PRE 14A 1 b64474prpre14a.htm BOSTON SCIENTIFIC CORPORATION pre14a
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.                )

     
Filed by the Registrant þ   Filed by a Party other than the Registrant o


Check the appropriate box:
þ Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o Definitive Proxy Statement
o Definitive Additional Materials
o Soliciting Material Pursuant to §240.14a-12

BOSTON SCIENTIFIC CORPORATION

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):
þ No fee required.
o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

o Fee paid previously with preliminary materials.

o   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

4) Date Filed:

       



Table of Contents

(BOSTON SCIENTIFIC LOGO)
 
Natick, Massachusetts
March   , 2007
 
Dear Boston Scientific Stockholder:
 
You are cordially invited to attend Boston Scientific Corporation’s Annual Meeting of Stockholders to be held on Tuesday, May 8, 2007, at 10:00 A.M. Eastern Time, at the Bank of America Northeast Training and Conference Center, 100 Federal Street, Boston, Massachusetts.
 
This year you are being asked to:
 
  •  re-elect four existing directors;
 
  •  approve amendments to our Certificate of Incorporation and Bylaws to declassify our Board of Directors;
 
  •  approve amendments to our Certificate of Incorporation and Bylaws to increase the maximum size of our Board of Directors from 15 to 20 directors;
 
  •  approve a stock option exchange program for Boston Scientific employees (excluding our executive officers and directors);
 
  •  vote upon a stockholder proposal to require executive stock retention guidelines;
 
  •  ratify the appointment of Ernst & Young LLP as our independent auditors for the 2007 fiscal year; and
 
  •  act upon such other business as may properly come before the annual meeting or any adjournment or postponement of the meeting.
 
These matters are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement.
 
Our Board of Directors urges you to read the accompanying Proxy Statement and recommends that you vote “FOR” all of the director nominees, the amendments to our Certificate of Incorporation and Bylaws declassifying the Board of Directors, the amendments to the Certificate of Incorporation and Bylaws increasing the maximum size of the Board from 15 to 20 directors, the stock option exchange program for Boston Scientific employees and the ratification of the appointment of Ernst & Young LLP as our independent auditors and “AGAINST” the stockholder proposal regarding executive stock retention guidelines.
 
At the meeting, you will be provided with the opportunity to ask questions.
 
The Board of Directors appreciates and encourages stockholder participation in the Company’s affairs. Whether or not you plan to attend the meeting, it is important that your shares be represented. Accordingly, we request that you sign, date and mail the enclosed proxy card in the envelope provided at your earliest convenience. Record holders may also vote electronically or telephonically by following the instructions printed on the enclosed proxy card.
 
Thank you for your cooperation.
 
Very truly yours,
 
Pete M. Nicholas
Chairman of the Board


(BOSTON SCIENTIFIC LOGO)
 
TABLE OF CONTENTS

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
PROPOSALS TO BE VOTED UPON
THE BOARD RECOMMENDS THAT YOU VOTE “FOR” THE ELECTION OF ALL FOUR OF THESE NOMINEES FOR DIRECTOR.
CORPORATE GOVERNANCE
MEETINGS AND BOARD COMMITTEES
EXECUTIVE COMPENSATION
COMPENSATION COMMITTEE REPORT
SUMMARY COMPENSATION TABLE
GRANTS OF PLAN BASED AWARDS
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END
OPTION EXERCISES AND STOCK VESTED
PENSION BENEFITS
NONQUALIFIED DEFERRED COMPENSATION
POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL
EQUITY COMPENSATION PLANS
DIRECTOR COMPENSATION
EXECUTIVE OFFICERS
STOCK OWNERSHIP
AUDIT COMMITTEE REPORT
Proposal 2: Approval of Amendments to our Certificate of Incorporation and Bylaws to provide for the Annual Election of Directors.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSAL 2. PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE SO VOTED UNLESS YOU OTHERWISE SPECIFY IN YOUR PROXY.
Proposal 3: Approval of Amendments to our Certificate of Incorporation and Bylaws to provide for an Increase in the Maximum Size of the Board.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSAL 3.
Proposal 4: Approval of stock option exchange program for Boston Scientific employees (excluding our executive officers and directors).
STOCK OPTION EXCHANGE RATIOS
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSAL 4. PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE SO VOTED UNLESS YOU OTHERWISE SPECIFY IN YOUR PROXY.
Proposal 5: Stockholder proposal requiring stock executive retention guidelines.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “AGAINST” PROPOSAL 5. PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE SO VOTED UNLESS YOU OTHERWISE SPECIFY IN YOUR PROXY.
Proposal 6: Ratification of Appointment of Independent Auditors.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
STOCKHOLDER PROPOSALS
HOUSEHOLDING
OTHER INFORMATION
Appendix A
Appendix B


Table of Contents

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
 
Natick, Massachusetts
March   , 2007
 
The Annual Meeting of Stockholders of Boston Scientific Corporation will be held at the Bank of America Northeast Training and Conference Center, 100 Federal Street, Boston, Massachusetts on Tuesday, May 8, 2007, at 10:00 A.M. Eastern Time, for the following purposes:
 
  (1)   To re-elect four existing Class III directors to serve until our 2010 Annual Meeting of Stockholders; provided, however, that if the amendments to our Certificate of Incorporation and Bylaws declassifying the Board of Directors as described below are approved, their term will expire at the 2008 Annual Meeting of Stockholders;
 
  (2)   To approve amendments to our Certificate of Incorporation and Bylaws that would declassify the Board of Directors;
 
  (3)   To approve amendments to our Certificate of Incorporation and Bylaws that would increase the maximum size of our Board of Directors from 15 to 20 directors;
 
  (4)   To approve a stock option exchange program for employees (excluding our executive officers and directors) providing for the exchange of stock options previously granted under our stock plans with an exercise price of $25.00 or more per share for a deferred stock unit (DSU) award (of a smaller number of DSUs than the number of exchanged stock options);
 
  (5)   To vote upon a stockholder proposal requiring executive stock retention guidelines;
 
  (6)   To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2007; and
 
  (7)   To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
 
Only stockholders of record at the close of business on March 9, 2007, are entitled to notice of and to vote at the meeting or any adjournments or postponements of the meeting.
 
So that your shares will be represented whether or not you attend the Annual Meeting, please sign, date and mail the enclosed proxy card in the postage-paid envelope provided at your earliest convenience. Record holders may also vote electronically or telephonically by following the instructions printed on your proxy card.
 
By Order of the Board of Directors
 
Paul W. Sandman
Secretary


Table of Contents

BOSTON SCIENTIFIC LOGO
 
One Boston Scientific Place
Natick, Massachusetts 01760
 
March   , 2007
 
 
PROXY STATEMENT
 
 
 
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
 
The Annual Meeting
 
The Annual Meeting of Stockholders of Boston Scientific Corporation will be held on Tuesday, May 8, 2007, at 10:00 A.M. Eastern Time, at the Bank of America Northeast Training and Conference Center, 100 Federal Street, Boston, Massachusetts. At this meeting, stockholders will be asked to re-elect four existing directors; approve amendments to our Certificate of Incorporation and Bylaws to declassify the Board of Directors; approve amendments to our Certificate of Incorporation and Bylaws to increase the maximum size of our Board of Directors from 15 to 20 directors; approve a stock option exchange program for Boston Scientific employees (excluding our executive officers and directors); vote upon a stockholder proposal requiring executive stock retention guidelines; and ratify the appointment of Ernst & Young LLP as our independent auditors for the 2007 fiscal year. Management will also report on our performance during fiscal 2006 and will respond to questions from stockholders. When used in this Proxy Statement, the terms “we,” “us,” “our” and “the Company” mean Boston Scientific Corporation and its divisions and subsidiaries.
 
Who is entitled to attend and vote at the Annual Meeting?
 
Stockholders of record at the close of business on March 9, 2007, are entitled to attend and vote at the Annual Meeting. Each share of our common stock is entitled to one vote. The proxy card provided with this proxy statement indicates the number of shares of Boston Scientific common stock that you own and are entitled to vote.
 
What do I need to bring to the Annual Meeting?
 
If your shares are registered in your name, you should bring proper identification to the meeting. If your shares are held in the name of a broker, trust, bank or another nominee, you will need to bring a proxy or letter from that broker, trust, bank or other nominee that confirms that you are the beneficial owner of those shares, along with proper identification.
 
What constitutes a quorum at the meeting?
 
The presence at the meeting, in person or by proxy, of the holders of a majority of the shares of our common stock outstanding on March 9, 2007, the record date, will constitute a quorum for purposes of the Annual Meeting. As of March 9, 2007, [            ] shares of Boston Scientific common stock were outstanding, with each share


Table of Contents

entitled to one vote. For purposes of determining whether a quorum exists, proxies received but marked “withhold” or “abstain” and “broker non-votes” (described below) will be counted.
 
How do I vote by proxy?
 
Your vote is very important. Whether or not you plan to attend the meeting, we urge you to complete, sign and date the enclosed proxy card and return it in the envelope provided. No postage is required if your proxy card is mailed in the United States. If you properly fill in your proxy card and our transfer agent receives it in time to vote at the meeting, your “proxy” (one of the individuals named on your proxy card) will vote your shares as you have directed. If you sign the proxy card but do not make specific choices, your proxy will vote your shares as recommended by the Board, as follows:
 
  (1)  FOR the re-election of each of the four existing director nominees;
 
  (2)  FOR the amendments to our Certificate of Incorporation and Bylaws to declassify the Board of Directors;
 
  (3)  FOR the amendments to our Certificate of Incorporation and Bylaws to increase the maximum size of the Board from 15 to 20 directors;
 
  (4)  FOR the stock option exchange program for Boston Scientific employees (excluding our executive officers and directors);
 
  (5)  AGAINST the stockholder proposal requiring executive stock retention guidelines; and
 
  (6)  FOR the ratification of the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2007.
 
If any other matter is properly presented at the meeting or if the meeting is to be postponed or adjourned, your proxy will vote your shares in accordance with his or her best judgment. At present, the Board knows of no other business that is intended to be brought before or acted upon at this Annual Meeting.
 
Can I vote by telephone or electronically?
 
If you are a registered stockholder (that is, if you hold your stock in your own name), you may vote by telephone or electronically through the Internet by following the instructions printed on your proxy card.
 
How do I vote if my shares are held by my broker?
 
If your shares are held by your broker in “street name,” you will need to instruct your broker (in the method required by your broker) how to vote your shares. Your broker may also offer electronic or telephonic voting.
 
What discretion does my broker have to vote my shares held in “street name”?
 
At this time, New York Stock Exchange rules allow your broker to vote your shares with respect to the election of directors and the ratification of our independent auditors, even if it does not receive instructions from you, so long as it holds your shares in its name. There are, however, certain matters with respect to which brokers do not have discretionary authority. These include the proposals to declassify the Board of Directors, increase the size of the Board of Directors, approve the stock option exchange program for Boston Scientific employees and adopt executive stock retention guidelines. If you do not instruct your broker how to vote with respect to these items, your broker may not vote “FOR” or “AGAINST” those proposals, but rather those votes will be considered “broker non-votes.” Shares represented by “broker non-votes” will, however, be counted in determining whether there is a quorum.


2


Table of Contents

Can I change my vote or revoke my proxy after I return my proxy card?
 
Yes. You may change your vote or revoke your proxy at any time before the proxy is exercised at the Annual Meeting. To change your vote, you may:
 
  •  mail a written notice “revoking” your earlier vote to our transfer agent, Mellon Investor Services LLC, Proxy Processing, P.O. Box 3510, South Hackensack, NJ 07606-9210;
 
  •  submit to our transfer agent a properly completed and signed proxy card with a later date;
 
  •  vote again telephonically or electronically (available until 11:00 p.m. Eastern Time on May 7, 2007); or
 
  •  vote in person at the Annual Meeting.
 
The last dated proxy or vote cast will be counted.
 
How do I vote in person?
 
If you plan to attend the Annual Meeting and vote in person, we will give you a ballot or a new proxy card when you arrive. However, if your shares are held in the name of your broker, trust, bank or other nominee, you must bring an account statement or letter from the broker, trust, bank or other nominee indicating that you were the beneficial owner of the shares on March 9, 2007, the record date for voting. Please bring proper identification to the Annual Meeting.
 
How do I vote my 401(k), GESOP and Guidant ESSOP shares?
 
If you participate in the Boston Scientific Corporation 401(k) Retirement Savings Plan (401(k) Plan), in our Global Employee Stock Ownership Plan (GESOP), or in the Guidant Employee Savings and Stock Ownership Plan (ESSOP) you will receive a single proxy card that covers all shares credited to your plan account(s) and shares that you own of record that are registered in the same name. If any of your plan accounts are not registered in the same name as your shares of record, you will receive separate proxy cards for your record and plan holdings. Properly completed and signed proxy cards will serve to instruct the trustees and fiduciaries of our 401(k) Plan, GESOP and ESSOP how to vote any Company shares held in these plans on your behalf. The 401(k) Plan, GESOP and ESSOP trustees and fiduciaries may vote at their discretion shares for which timely instructions are not received.
 
Who is our transfer agent?
 
Our transfer agent is Mellon Investor Services LLC. Representatives of Mellon Investor Services LLC will tabulate the votes and act as inspectors of election at the Annual Meeting.
 
What vote is required to approve each proposal?
 
  (1)  For the Election of Directors. With respect to Proposal 1, the four nominees for director receiving the most votes from those shares present or represented at the Annual Meeting will be elected. If you do not vote for a particular nominee, or you withhold authority for one or all nominees, your vote will be counted for purposes of determining whether there is a quorum, but will not count either “for” or “against” the nominee.
 
  (2)  For the Declassification of the Board of Directors and the Increase in the Size of the Board. With respect to Proposals 2 and 3, the affirmative vote of eighty percent (80%) of our outstanding shares is required to approve the amendments to our Certificate of Incorporation and Bylaws which would provide for the declassification of our Board of Directors and an increase in the maximum size of our Board of Directors.
 
  (3)  For All Other Matters. For the approval of the stock option exchange program, the stockholder proposal requiring executive stock retention guidelines and the ratification of the appointment of Ernst & Young LLP as our auditors for the year ending December 31, 2007, the affirmative vote of a majority of shares participating in the voting on such proposal is required for approval. At present, the Board knows of no matters other than these to be presented for stockholder action at the Annual Meeting. A properly executed


3


Table of Contents

  proxy marked “abstain” with respect to any of these matters will not be voted “for” or “against” the proposal(s), but will be counted for purposes of determining the number of votes cast. Accordingly, an abstention will have the effect of a negative vote.
 
Is voting confidential?
 
Yes. We will treat proxy cards, ballots and voting tabulations as confidential. Generally, only the inspectors of election and certain employees associated with processing proxy cards, counting the vote or administering the meeting have access to these documents.
 
How is the Company soliciting proxies?
 
We have retained [     ] to assist with the solicitation of proxies. [     ] will receive customary fees as compensation for its services plus reimbursement for its related out-of-pocket expenses. We and [     ] expect to solicit proxies chiefly by mail, but we or [     ] may also solicit proxies in person, by electronic delivery, the internet, telephone or other media. No additional compensation will be paid to our directors, officers or other employees in connection with this solicitation. All solicitation expenses, including costs of preparing, assembling and mailing proxy material, will be borne by us.


4


Table of Contents

 
PROPOSALS TO BE VOTED UPON
 
Proposal 1: Re-Election of Existing Directors.
 
Currently, our Board of Directors consists of 14 directors and is divided into three approximately equal classes. Each class serves for a period of three years. The classes are arranged so that the terms of the directors in each class expire at successive Annual Meetings. Occasionally, a director may be elected for a shorter term in order to keep the number of directors in each class approximately equal. The term of our Class III directors expires at this Annual Meeting. The Board has nominated each of the following incumbent Class III directors to stand for re-election for a term of three years expiring at our 2010 Annual Meeting; provided, however, that, if Proposal 2 is approved, they will be elected for a one-year term, expiring at our 2008 Annual Meeting of Stockholders and until his or her successor has been elected and qualified: Ursula M. Burns, Marye Anne Fox, Ph.D., N.J. Nicholas, Jr. and John E. Pepper.
 
We know of no reason why any of the nominees would be unable to serve as a director. However, should such a situation arise, the Board may designate a substitute nominee or, alternatively, reduce the number of directors to be elected. If a substitute nominee is selected, the persons named as proxies will vote for that substitute nominee. Any vacancies not filled at the Annual Meeting may be filled by the Board.
 
Class III Director Nominees (Term Expires 2010, or if Proposal 2 is approved, 2008)
 
Name
 
Ursula M. Burns
Age 48
Director since 2002
Ursula M. Burns is President of Business Group Operations and Corporate Senior Vice President of Xerox Corporation. Ms. Burns joined Xerox in 1980, subsequently advancing through several engineering and management positions. Ms. Burns served as Vice President and General Manager, Departmental Business Unit from 1997 to 1999, Senior Vice President, Worldwide Manufacturing and Supply Chain Services from 1999 to 2000, Senior Vice President, Corporate Strategic Services from 2000 to October 2001 and President of Document Systems and Solutions Group until her most recent appointment in January 2003. She serves on the boards of directors of American Express Corporation, the National Association of Manufacturers, the FIRST (For Inspiration and Recognition of Science and Technology) Foundation and the Rochester Business Alliance and is a Trustee of the University of Rochester. Ms. Burns earned a B.S. degree from Polytechnic Institute of New York and an M.S. degree in mechanical engineering from Columbia University.
 
Marye Anne Fox
Age 59
Director since 2001
Marye Anne Fox has been Chancellor of the University of California, San Diego and Distinguished Professor of Chemistry since August 2004. Prior to that, she served as Chancellor of North Carolina State University and Distinguished University Professor of Chemistry from 1998 to 2004. From 1976 to 1998, she was a member of the faculty at the University of Texas, where she taught chemistry and held the Waggoner Regents Chair in Chemistry from 1991 to 1998. She served as the University’s Vice President for Research from 1994 to 1998. Dr. Fox is the Co-Chair of the National Academy of Sciences’ Government-University-Industry Research Roundtable and serves on President Bush’s Council of Advisors on Science and Technology. She has served as the Vice Chair of the National Science Board. She also serves on the boards of a number of other scientific, technological and civic organizations, and is a member of the boards of directors of Red Hat Corp., Pharmaceutical Product Development, Inc., Burroughs-Wellcome Fund, W.R. Grace Co. and the Camille and Henry Dreyfus Foundation. She has been honored by a wide range of educational and


5


Table of Contents

Class III Director Nominees (Term Expires 2010 or if Proposal 2 is approved, 2008) (continued)
 
professional organizations, and she has authored more than 350 publications, including five books. Dr. Fox holds a B.S. in Chemistry from Notre Dame College, an M.S. in Organic Chemistry from Cleveland State University, and a Ph.D. in Organic Chemistry from Dartmouth College.
 
N.J. Nicholas, Jr
Age 67
Director since 1994
N.J. Nicholas, Jr. is a private investor. Previously, he served as President of Time, Inc. from September 1986 to May 1990 and Co-Chief Executive Officer of Time Warner, Inc. from May 1990 until February 1992. Mr. Nicholas is a director of Xerox Corporation and Time Warner Cable, Inc. He has served as a director of Turner Broadcasting and a member of the President’s Advisory Committee for Trade Policy and Negotiations and the President’s Commission on Environmental Quality. Mr. Nicholas is Chairman of the Board of Trustees of Environmental Defense and a member of the Council on Foreign Relations. Mr. Nicholas received an A.B. degree from Princeton University and an M.B.A. degree from Harvard Business School. He is also the brother of Pete Nicholas, Chairman of the Board.
 
John E. Pepper
Age 68
Director since 2003
John E. Pepper has been a Director of Boston Scientific since 2003 and he previously served as a director of Boston Scientific from November 1999 to May 2001. Mr. Pepper is the Chief Executive Officer and director of the National Underground Railroad Freedom Center. Previously he served as Vice President for Finance and Administration of Yale University from January 2004 to December 2005. Prior to that, he served as Chairman of the executive committee of the board of directors of The Procter & Gamble Company until December 2003. Since 1963, he served in various positions at Procter & Gamble, including Chairman of the Board from 2000 to 2002, Chief Executive Officer and Chairman from 1995 to 1999, President from 1986 to 1995 and director since 1984. Mr. Pepper is Chairman of the board of directors of The Walt Disney Company, and is a member of the executive committee of the Cincinnati Youth Collaborative. Mr. Pepper graduated from Yale University in 1960 and holds honorary doctoral degrees from Yale University, The Ohio State University, Xavier University, Mount St. Joseph College and St. Petersburg University (Russia).
 
THE BOARD RECOMMENDS THAT YOU VOTE “FOR” THE ELECTION OF
ALL FOUR OF THESE NOMINEES FOR DIRECTOR.


6


Table of Contents

The following directors hold the Company’s remaining Board seats:
 
Class I Directors (Term Expires 2008)
 
Nancy-Ann DeParle
Age 50
Director since 2006
Nancy-Ann DeParle has been a Director of Boston Scientific since our acquisition of Guidant in April 2006. Since August 2006, Ms. DeParle has been a Managing Director of CCMP Capital Advisors, LLC. Previously, she had been a Senior Advisor for JP Morgan Partners and an Adjunct Professor at The Wharton School of the University of Pennsylvania from 2000 to 2006, and prior to that she served as the Administrator of the Health Care Financing Administration (HCFA) (now the Centers for Medicare and Medicaid Services) from 1997 to 2000. Prior to her role at HCFA, Ms. DeParle was the Associate Director for Health and Personnel at the White House Office of Management and Budget and served as commissioner of the Tennessee Department of Human Services. She also has worked as a lawyer in private practice in Nashville, Tennessee and Washington, DC. Ms. DeParle is a director of Cerner Corporation, DaVita Inc. and Triad Hospitals, Inc. Ms. DeParle is a trustee of the Robert Wood Johnson Foundation and serves on the Medicare Payment Advisory Commission. Ms. DeParle received a B.A. degree from the University of Tennessee, a J.D. from Harvard Law School, and B.A. and M.A. degrees in Politics and Economics from Balliol College of Oxford University, where she was a Rhodes Scholar.
 
Ray J. Groves
Age 71
Director since 1999
From 2001 to 2005, Ray J. Groves served in various roles at Marsh Inc., including President, Chairman and Senior Advisor, and is a former member of the board of directors of its parent company, Marsh & McLennan Companies, Inc. He served as Chairman of Legg Mason Merchant Banking, Inc. from 1995 to 2001. Mr. Groves served as Chairman and Chief Executive Officer of Ernst & Young for 17 years until his retirement in 1994. Mr. Groves currently serves as a member of the boards of directors of Electronic Data Systems Corporation, Overstock.com and the Colorado Physicians Insurance Company. Mr. Groves is a member of the Council on Foreign Relations. He is a former member of the Board of Governors of the American Stock Exchange and the National Association of Securities Dealers. Mr. Groves is former Chairman of the board of directors of the American Institute of Certified Public Accountants. He is a member and former Chair of the board of directors of The Ohio State University Foundation and a member of the Dean’s Advisory Council of the Fisher College of Business. He is a former member of the Board of Overseers of The Wharton School of the University of Pennsylvania and served as the Chairman of its Center for the Study of the Service Sector. Mr. Groves is a managing director of the Metropolitan Opera Association and a director of the Collegiate Chorale. Mr. Groves received a B.S. degree from The Ohio State University.
 
Pete M. Nicholas
Age 65
Director since 1979
Pete M. Nicholas, a co-founder of Boston Scientific, has been Chairman of the Board since 1995. He served as our Chief Executive Officer from 1979 to March 1999 and Co-Chairman of the Board from 1979 to 1995. Prior to joining Boston Scientific, he was corporate director of marketing and general manager of the Medical Products Division at Millipore Corporation, a medical device company, and served in various sales, marketing and general management positions at Eli Lilly and Company. He is currently Chairman Emeritus of the Board of Trustees of Duke University. Mr. Nicholas is also a Fellow of the National Academy of Arts and Sciences and a member of the Trust for that organization. He has also served on several for profit and not-for-profit boards. Mr. Nicholas is a member of the Massachusetts Business Roundtable,


7


Table of Contents

Class I Directors (Term Expires 2008) (continued)
 
Massachusetts Business High Technology Council, CEOs for Fundamental Change in Education and the Boys and Girls Club of Boston. After college, Mr. Nicholas served as an officer in the U.S. Navy, resigning his commission as lieutenant in 1966. Mr. Nicholas received a B.A. degree from Duke University, and an M.B.A. degree from The Wharton School of the University of Pennsylvania. He is also the brother of N.J. Nicholas, Jr., one of our directors.
 
Warren B. Rudman
Age 76
Director since 1999
Senator Warren B. Rudman has been Of Counsel to the international law firm Paul, Weiss, Rifkind, Wharton, and Garrison LLP since January 2003. Previously, he was a partner of that firm since 1992. Prior to joining the firm, he served two terms as a U.S. Senator from New Hampshire from 1980 to 1992. He serves on the boards of directors of Collins & Aikman Corporation and several funds managed by the Dreyfus Corporation. He is the founding co-chairman of the Concord Coalition. Senator Rudman received a B.S. from Syracuse University and an LL.B. from Boston College Law School and served in the U.S. Army during the Korean War.
 
James R. Tobin
Age 62
Director since 1999
James R. Tobin is our President and Chief Executive Officer. Prior to joining Boston Scientific in March 1999, Mr. Tobin served as President and Chief Executive Officer of Biogen, Inc. from 1997 to 1998 and Chief Operating Officer of Biogen from 1994 to 1997. From 1972 to 1994, Mr. Tobin served in a variety of executive positions with Baxter International, including President and Chief Operating Officer from 1992 to 1994. Previously, he served at Baxter as Managing Director in Japan, Managing Director in Spain, President of Baxter’s I.V. Systems Group and Executive Vice President. Mr. Tobin currently serves on the boards of directors of Curis, Inc. and Applera Corporation. Mr. Tobin holds an A.B. from Harvard College and an M.B.A. from Harvard Business School. Mr. Tobin also served in the U.S. Navy from 1968 to 1972 where he achieved the rank of lieutenant.


8


Table of Contents

     
    Class II Directors (Term Expires 2009)
John E. Abele
Age 70
Director since 1979
  John E. Abele, our co-founder, was our Treasurer from 1979 to 1992, our Co-Chairman from 1979 to 1995 and our Vice Chairman and Founder, Office of the Chairman from February 1995 to March 1996. Mr. Abele is also the owner of The Kingbridge Centre and Institute, a 120-room conference center in Ontario that provides special services and research to businesses, academia and government. He was President of Medi-tech, Inc. from 1970 to 1983, and prior to that served in sales, technical and general management positions for Advanced Instruments, Inc. Mr. Abele serves on the board of directors of Color Kinetics, is the Chairman of the Board of the FIRST (For Inspiration and Recognition of Science and Technology) Foundation and is also a member of numerous not-for-profit boards. Mr. Abele received a B.A. degree from Amherst College.
     
Joel L. Fleishman
Age 72
Director since 1992
  Joel L. Fleishman is a Professor of Law and Public Policy at Duke University where he has served in various administrative positions, including First Senior Vice President, since 1971. Mr. Fleishman is a founding member of the governing board of the Duke Center for Health Policy Research and Education and was the founding director from 1971 to 1983 of Duke University’s Terry Sanford Institute of Public Policy. He is the director of the Samuel and Ronnie Heyman Center for Ethics, Public Policy and the Professions and the director of the Duke University Philanthropic Research Program. From 1993 to 2001, Mr. Fleishman took a part-time leave from Duke University to serve as President of the Atlantic Philanthropic Service Company, the U.S. program staff of Atlantic Philanthropies. Mr. Fleishman also serves as a member of the Board of Trustees of The John and Mary Markle Foundation, Chairman of the Board of Trustees of the Urban Institute, Chairman of The Visiting Committee of the Kennedy School of Government, Harvard University, and as a director of Polo Ralph Lauren Corporation and the James River Insurance Group. Mr. Fleishman received A.B., M.A. and J.D. degrees from the University of North Carolina at Chapel Hill, and an LL.M. degree from Yale University.
     
Ernest Mario
Age 68
Director since 2001
  Ernest Mario is currently the Chairman of Reliant Pharmaceuticals. From 2003 to 2006, he was also the chief executive officer of Reliant Pharmaceuticals. Prior to joining Reliant Pharmaceuticals in April 2003, he was the Chairman of IntraBiotics Pharmaceuticals, Inc. from April 2002 to April 2003. Dr. Mario also served as Chairman and Chief Executive Officer of Apothogen, Inc., a pharmaceutical company, from January 2002 to April 2002 when Apothogen was acquired by IntraBiotics. Dr. Mario served as the Chief Executive of Glaxo Holdings plc from 1989 until March 1993 and as Deputy Chairman and Chief Executive from January 1992 until March 1993. From 1993 to 1997, Dr. Mario served as Co-Chairman and Chief Executive Officer of ALZA Corporation, a research-based pharmaceutical company with leading drug-delivery technologies, and Chairman and Chief Executive Officer from 1997 to 2001. Dr. Mario presently serves on the boards of directors of Maxygen, Inc., Alexza Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc. He is also a Trustee of Duke University and Chairman of the Board of the Duke University Health System. He is a past Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to the pharmacy schools at the University of Maryland, the University of Rhode Island and The Ernest Mario School of Pharmacy at Rutgers University. Dr. Mario holds a B.S. in Pharmacy from Rutgers, and an M.S. and a Ph.D. in Physical Sciences from the University of Rhode Island.


9


Table of Contents

     
    Class II Directors (Term Expires 2009) (continued)
Uwe E. Reinhardt
Age 69
Director since 2002
  Uwe E. Reinhardt is the James Madison Professor of Political Economy and Professor of Economics and Public Affairs at Princeton University, where he has taught since 1968. Dr. Reinhardt is a senior associate of the University of Cambridge, England and serves as a Trustee of Duke University and the Duke University Health System, H&Q Healthcare Investors, H&Q Life Sciences Investors and Hambrecht & Quist Capital Management LLC. He is also the Commissioner of the Kaiser Family Foundation Commission on Medicaid and the Uninsured and a member of the boards of directors of Amerigroup Corporation and Triad Hospitals, Inc. Dr. Reinhardt is a member of the Institute of Medicine of the National Academy of Sciences. Dr. Reinhardt received a Bachelor of Commerce degree from the University of Saskatchewan, Canada and a Ph.D. in economics from Yale University.
     
Kristina M. Johnson
Age 49
Director since 2006
  Kristina M. Johnson has been a Director of Boston Scientific since our acquisition of Guidant in April 2006. Dr. Johnson is the Dean of the Pratt School of Engineering at Duke University, a position she has held since July 1999. Previously, she served as a professor in the Electrical and Computer Engineering Department, University of Colorado, from 1994 to 1999 and as associate and assistant professor from 1985. She served as deputy director and later as director of the National Science Foundation Engineering Research Center for Optoelectronics Computing Systems at the University of Colorado, Boulder, from 1992 to 1997. Dr. Johnson is a co-founder of the Colorado Advanced Technology Institute Center of Excellence in Optoelectronics and serves as a director of Minerals Technologies, Inc., AES Corporation and Nortel Corporation. Dr. Johnson also serves on the board of directors of the Society of Photo-Instrumentation Engineers and Duke Children’s Classic to benefit Duke Children’s Hospital. Dr. Johnson was a Fulbright Faculty Scholar in the Department of Electrical Engineering at the University of Edinburgh, Scotland, from 1991 to 1992 and a NATO Post-Doctoral Fellow at Trinity College, Dublin, Ireland, from 1983 to 1985. Dr. Johnson received B.S., M.S. and Ph.D. degrees in electrical engineering from Stanford University.


10


Table of Contents

 
CORPORATE GOVERNANCE
 
Our Board of Directors has established a Corporate Governance Manual to guide the operation and direction of the Board and its committees. The Corporate Governance Manual consists of our Corporate Governance Guidelines, charters for the standing committees of the Board and our Code of Conduct. Current copies of our Corporate Governance Guidelines, committee charters and Code of Conduct are available on our website at www.bostonscientific.com and may also be obtained free of charge by written request to: Investor Relations, One Boston Scientific Place, Natick, MA 01760-1537.
 
Director Independence
 
Our Corporate Governance Guidelines require that a significant majority of the Board be independent. Our common stock is listed on the New York Stock Exchange (NYSE). To be considered independent under the NYSE rules, the Board must determine that a director does not have a direct or indirect material relationship with the Company. In addition, a director is not independent if:
 
  •  The director is, or has been within the last three years, an employee of the Company or if the director has an immediate family member who is, or has been within the last three years, an executive officer of the Company.
 
  •  The director has received, or has an immediate family member who has received, during any 12-month period within the last three years, more than $100,000 in direct compensation from the Company, other than director and committee fees and pension or other forms of deferred compensation for prior service (provided such compensation is not contingent in any way on continued service).
 
  •  (A) The director or the director’s immediate family member is a current partner of the Company’s internal or external auditor; (B) the director is a current employee of such auditing firm; (C) the director has an immediate family member who is a current employee of such auditing firm and who participates in the firm’s audit, assurance or tax compliance (but not tax planning) practice; or (D) the director or the director’s immediate family member was within the last three years (but is no longer) a partner or employee of such auditing firm and personally worked on the Company’s audit within that time.
 
  •  The director or the director’s immediate family member is, or has been within the last three years, employed as an executive officer of another company where any of the Company’s present executive officers serves or served at the same time on that other company’s compensation committee.
 
  •  The director is a current employee, or the director’s immediate family member is a current executive officer, of a company that has made payments to or received payments from the Company for property or services in an amount which, in any of the last three fiscal years, exceeds the greater of $1 million or 2% of such other company’s consolidated gross revenues.
 
The Board also has established the following categorical standards, which can be found in our Corporate Governance Guidelines, to assist it in determining director independence in accordance with the NYSE rules:
 
  •  Commercial Relationships.  The following commercial relationships are not considered material relationships that would impair a director’s independence: (i) if a director of the Company is an executive officer or an employee of, or an immediate family member of a director is an executive officer of, another company that does business with the Company and the annual sales to, or purchases from, the Company are less than 1% of the annual revenues of such other company, and (ii) if a director of the Company is an executive officer of another company which is indebted to the Company, or to which the Company is indebted, and the total amount of either company’s indebtedness to the other is less than 2% of the total consolidated assets of the company for which he or she serves as an executive officer.
 
  •  Charitable Relationships.  The following charitable relationship will not be considered a material relationship that would impair a director’s independence: if a director, or an immediate family member of the director, serves as an executive officer, director or trustee of a charitable organization, and the Company’s discretionary charitable contributions to that charitable organization in any single fiscal year are less than 1% (or $500,000, whichever is less) of that charitable organization’s annual consolidated gross revenues.


11


Table of Contents

 
  •  Personal Relationships.  The following personal relationship will not be considered to be a material relationship that would impair a director’s independence: if a director, or immediate family member of the director, receives from, or provides to, the Company products or services in the ordinary course and on substantially the same terms as those prevailing at the time for comparable products or services provided to unaffiliated third parties.
 
For relationships not qualifying within the foregoing guidelines, the determination of whether the relationship is material, and therefore whether the director is independent, shall be made by the directors who satisfy the foregoing independence guidelines. For purposes of these guidelines, “immediate family member” has the meaning defined in the NYSE rules. The Board monitors its compliance with the NYSE requirements for director independence on an ongoing basis.
 
In accordance with current NYSE rules and our own categorical standards of independence, the Board of Directors has determined that the following non-employee directors are deemed “independent” and have no direct or indirect material relationship with the Company, except as a director and stockholder: Ursula M. Burns, Nancy-Ann DeParle, Joel L. Fleishman, Marye Anne Fox, Ray J. Groves, Kristina M. Johnson, Ernest Mario, John E. Pepper, Uwe E. Reinhardt and Warren B. Rudman. Currently, ten out of the fourteen members of our Board are independent. The Board has determined that James R. Tobin, our President and CEO, is not independent because he is an employee of Boston Scientific; Pete Nicholas and John Abele are not independent because they were employees of Boston Scientific within the last three years, retiring in 2005; and N.J. Nicholas, Jr. is not independent because he is the brother of Pete Nicholas, who received more that $100,000 in direct compensation from Boston Scientific within the last three years. The Board reviewed Boston Scientific’s relationship with Xerox Corporation, of which Ursula Burns is an executive officer, and determined that that relationship falls below our categorical standards for commercial relationships, was established in the ordinary course of business on an arms-length basis and is not material to Boston Scientific, Xerox, or Ms. Burns.
 
Nominations for Directors
 
Our Nominating and Governance Committee is responsible for identifying and recommending nominees for election to the Board. The Nominating and Governance Committee believes that all director nominees must, at a minimum, meet the general criteria outlined in our Corporate Governance Guidelines (which are available on our website at www.bostonscientific.com).
 
Generally, directors should be individuals who have succeeded in their particular field and who demonstrate integrity, reliability, knowledge of corporate affairs and an ability to work well with others. Directors should also satisfy at least one of the following criteria:
 
  •  Demonstrated management ability at senior levels in successful organizations;
 
  •  Current or recent employment in positions of significant responsibility and decision making;
 
  •  Expertise in leading rapidly growing multi-national organizations; or
 
  •  Current and prior experience related to anticipated board and committee responsibilities in other areas of importance to the Company.
 
The qualifications of candidates recommended by stockholders will be reviewed and considered by the Nominating and Governance Committee with the same degree of care and consideration as candidates for nomination to the Board submitted by Board members and our Chief Executive Officer. Under our Bylaws and SEC regulations, any stockholder proposal or director nominations for the 2008 Annual Meeting of Stockholders must be received on or before December 12, 2007 in order to be considered for inclusion in our 2008 Proxy Statement. Please address your proposal, recommendation or nomination to our Secretary at Boston Scientific Corporation, One Boston Scientific Place, Natick, MA 01760-1537.
 
Communications with the Board
 
Stockholders and other interested parties who wish to communicate directly with any member of our Board of Directors, or our non-management directors as a group, may do so by writing to the Board of Directors, Boston


12


Table of Contents

Scientific Corporation, c/o General Counsel, One Boston Scientific Place, Natick, MA 01760-1537 or by contacting the non-management directors via email at non-managementdirectors@bsci.com. In addition, stockholders and other interested parties may contact the chairperson of each committee at the following email addresses: AuditCommittee@bsci.com, StrategicInvestmentCommittee@bsci.com, NominatingandGovernanceCommittee@bsci.com, QualityCommittee@bsci.com and CompensationCommittee@bsci.com. The Board has authorized the office of our General Counsel to review and organize, but not screen, communications from stockholders and/or interested parties and deliver them to the Board.
 
Board Service Limitation
 
Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including our board) and the CEO may not sit on more than one public company board (in addition to our board).
 
Arrangements for the Election of Directors
 
We do not have any current arrangements relating to the election of directors to our Board.
 
Separation of Chairman and Chief Executive Officer
 
We separate the roles of Chairman of the Board and Chief Executive Officer. Our Chairman is Pete M. Nicholas and our Chief Executive Officer is James R. Tobin.
 
Related Party Transactions
 
Our Board of Directors has adopted a new written related party transaction policy to monitor transactions, arrangements or relationships in which Boston Scientific and any of the following have an interest: an executive officer or director, an immediate family member of an executive officer or director, a person or entity holding more than a 5% beneficial interest in our common stock, or any entity in which any of the foregoing persons is employed, is a principal, or has a 10% or greater beneficial ownership interest. The policy covers any related party transaction that meets the minimum threshold for disclosure under the relevant SEC rules (generally, transactions involving amounts exceeding $120,000 in which a related person has a direct or indirect material interest).
 
Our Executive Vice President and General Counsel is responsible for identifying any potential related party transactions and, if he determines that the existing or proposed transaction constitutes a related party transaction under the policy, he will provide relevant details and analysis of the related party transaction to the Audit Committee. The General Counsel will provide an annual summary to the Audit Committee of all transactions or relationships which he considered under this policy, including those that he determined do not constitute a related party transaction. If the General Counsel has an interest in a potential related party transaction, he will provide all relevant information to our Chief Executive Officer or his designee, who will review with counsel to determine whether the proposed transaction is a related party transaction. The Chief Executive Officer or his designee will present the information to the Audit Committee that would otherwise be provided by the General Counsel. The Audit Committee reviews relevant information concerning any existing or proposed transaction contemplated by the Company with an entity that is the subject of a disclosed relationship, and approves or disapproves the transaction, with or without conditions or additional protections for the Company. Our related party transactions policy can be found in our Corporate Governance Guidelines posted on our website.
 
During 2006, we made payments of approximately $4.5 million to Arnold & Porter LLP, a law firm of which the brother of Paul W. Sandman, our General Counsel, is an equity partner. Mr. Sandman’s brother did not perform any services for us. At the time these transactions occurred, they were not subject to our current related party transaction policy. We will continue to monitor and, if appropriate in 2007, approve this relationship under our newly implemented written related party transactions policy.
 
Until August 2006, Nancy-Ann DeParle, one of our directors, was a Senior Advisor to JP Morgan Partners, LLC, the private equity division of JP Morgan Chase & Co. JP Morgan Securities Inc., an indirect wholly owned subsidiary of JP Morgan Chase & Co., acted as a financial advisor to Guidant in connection with our acquisition of


13


Table of Contents

Guidant and as a financial advisor to Boston Scientific in connection with several of our credit facilities and public debt offerings. During 2006, Guidant made payments of approximately $50.3 million to JP Morgan in connection with the Guidant acquisition and Boston Scientific made payments of approximately $1.5 million to JP Morgan in connection with our credit facilities and public debt offerings. At the time these transactions occurred, they were not subject to our current related party transaction policy. In August 2006, Ms. DeParle became a Managing Director of CCMP Capital Advisors, LLC, a private equity firm formed by the buyout professionals of JP Morgan Partners, LLC, which is independent from its former parent company.
 
Several of our directors are affiliated with Duke University. Joel L. Fleishman has been employed by Duke University since 1971 and is currently a Professor of Law and Public Policy there. Ernest Mario is a Trustee of Duke University and Chairman of the Board of the Duke University Health System. Pete M. Nicholas received his B.A. degree from Duke University and is Chairman Emeritus of the Board of Trustees of Duke University. Uwe E. Reinhardt is a Trustee of Duke University and the Duke University Health System. Kristina M. Johnson is the Dean of the Pratt School of Engineering at Duke University. We also conduct business in the ordinary course with the medical center and other healthcare facilities at Duke University. We will monitor these relationships and, if appropriate in 2007, approve transactions with Duke-affiliated entities under our newly implemented written related party transactions policy.
 
From time to time, our directors or executive officers may invest in venture funds in which we are also an investor. These venture funds are generally managed by unaffiliated third parties. Our decisions, and the decisions of our directors and officers, to invest in these ventures are made independently of each other.


14


Table of Contents

 
MEETINGS AND BOARD COMMITTEES
 
Board Meetings
 
The Board met 9 times in fiscal year 2006. Each director attended more than 75% of the meetings of the Board and of the Committees on which he or she served.
 
Executive Sessions
 
The non-management directors or independent directors meet in executive sessions without management directors at most of our regularly scheduled Board meetings and at such other times as they deem appropriate but, in any event, at least once annually. The chairperson of the Nominating and Governance Committee presides at executive sessions of non-management directors, and in his or her absence, the chairperson of the Audit Committee will preside, and in his or her absence, the chairperson of the Executive Compensation and Human Resources Committee will preside.
 
Director Attendance at Board, Board Committee and Annual Meetings
 
Directors are expected to prepare for and use reasonable efforts to participate in all Board meetings and meetings of the committees on which they serve. The Board and each committee will meet as frequently as necessary to properly discharge their responsibilities, provided that the full Board will meet at least four times per year. Generally, the Board meets in February, May, July, October and December. In addition, directors are expected to use reasonable efforts to attend Annual Meetings of Stockholders. Fourteen out of 14 of our directors attended last year’s Annual Meeting. We also held a special meeting of stockholders on March 31, 2006, in connection with seeking approval for the Guidant transaction, which three out of 12 of our directors attended.
 
Committees of the Board
 
Our Board of Directors has standing Audit, Executive Compensation and Human Resources, Nominating and Governance, Finance and Strategic Investment, and Compliance and Quality Committees. The charters of the standing Committees of the Board are available on our website at www.bostonscientific.com. Our Board also establishes special committees from time to time.
 
Committee Independence
 
All of the members of the Audit Committee, Executive Compensation and Human Resources Committee, Nominating and Governance Committee and the Compliance and Quality Committee are independent directors under the criteria for independence required by law, the NYSE rules and under our categorical standards of independence. A significant majority of the members of the Finance and Strategic Investment Committee are independent directors.


15


Table of Contents

 
Membership on each committee is set forth in the following table as of March 1, 2007:
 
BOARD COMMITTEE MEMBERSHIP
As of March 1, 2007
 
                                         
          Executive
          Finance
       
          Compensation
    Nominating
    and
    Compliance
 
          and Human
    and
    Strategic
    and
 
    Audit
    Resources
    Governance
    Investment
    Quality
 
Name
  Committee     Committee     Committee     Committee     Committee  
 
Ursula M. Burns
            *               *       +  
Nancy-Ann DeParle
            *                       *  
Joel L. Fleishman
    +               *               *  
Marye Anne Fox
    *                       *          
Ray J. Groves
            *       +                  
Kristina M. Johnson
            *               *          
Ernest Mario
    *                       +       *  
N.J. Nicholas, Jr. 
                            *          
John E. Pepper
    *                       *          
Uwe E. Reinhardt
    *               *               *  
Warren B. Rudman
            +       *                  
James R. Tobin
                            *          
 
Committee Member
 
Committee Chair
 
Audit Committee
 
Our Audit Committee met 9 times during fiscal year 2006. The Board has determined that our Audit Committee is comprised exclusively of non-employee directors, all of whom meet the independence requirements of the NYSE and the SEC. The Board has also determined that Ernest Mario, John E. Pepper and Uwe E. Reinhardt is each an “audit committee financial expert” as that term is defined in the rules and regulations of the SEC for purposes of Section 407 of the Sarbanes-Oxley Act of 2002. Mr. Reinhardt is an “audit committee financial expert” by virtue of having taught financial accounting for over 30 years at Princeton University.
 
The primary purpose of the Audit Committee is to provide oversight to our accounting and financial reporting processes and audits of our financial statements. The Audit Committee primarily provides assistance to our Board of Directors in the areas of corporate accounting, internal control, independent audit and reporting practices, and maintains, by way of regularly scheduled meetings, a direct line of communication among our directors, management, our internal auditors and our independent auditors. The Audit Committee appoints our independent auditors, evaluates their qualifications, independence and performance, and reviews their reports and other services. In addition, the Audit Committee pre-approves audit, audit-related and non-audit services performed for us by our independent auditors and has the right to terminate our independent auditors. It is also responsible for monitoring our adherence to established legal and regulatory requirements, corporate policies, including our related party transactions policy, and ethics and integrity programs and practices. The Audit Committee is governed by a written charter approved by our Board of Directors which is subject to review on an annual basis. In accordance with the rules and regulations of the SEC and the NYSE, the Audit Committee Report can be found on page [  ] of this Proxy Statement.
 
Executive Compensation and Human Resources Committee
 
Our Executive Compensation and Human Resources Committee (the Compensation Committee) met 7 times during fiscal year 2006. The Compensation Committee is comprised of non-employee directors, all of whom meet


16


Table of Contents

the independence requirements of the NYSE and the SEC. As outlined in its written charter, the Compensation Committee has the authority, among other things, to:
 
  •  Determine and approve (and make recommendations to the Board regarding) our CEO’s compensation, based on the performance evaluation by and recommendations of the Chairman of the Board and the Nominating and Governance Committee;
 
  •  Review, oversee and determine the total compensation package for our other executive officers;
 
  •  Review and make recommendations to the Board regarding employment, consulting, retirement, severance and change in control agreements, indemnification agreements and other arrangements proposed for our executive officers, including conducting a periodic review to evaluate these arrangements for continuing appropriateness;
 
  •  Review and make recommendations to the Board regarding the compensation of our directors; and
 
  •  Adopt and periodically review a comprehensive statement of executive compensation philosophy, strategy and principles.
 
The Compensation Committee may delegate its authority and duties to subcommittees or individual members of the Committee, as it deems appropriate in accordance with applicable laws and regulations. The Compensation Committee has delegated authority to our CEO to make equity grants to new hires who are not executive officers. These grants are reviewed and ratified by the Compensation Committee at its next regularly scheduled meeting. Our CEO makes recommendations to the Compensation Committee regarding the amount and form of compensation of our executives (other than himself), based upon their performance for the year and their achievement of the goals set at the beginning of the year. The Chairman of the Board and the Governance Committee make recommendations to the Compensation Committee regarding the amount and form of CEO compensation, based upon his performance for the year and his achievement of the goals set at the beginning of the year. The Compensation Committee then makes a recommendation to the Board, and the independent directors of the full Board approve the CEO compensation, in consideration of this recommendation. Our Executive Vice President of Human Resources, in consultation with our compensation consultants and the Chairman of the Board, makes recommendations to the Compensation Committee regarding director compensation. The Compensation Committee would then make a recommendation regarding director compensation for approval by the full Board of Directors.
 
The Compensation Committee may also retain compensation consultants to assist it in evaluating executive compensation and may retain counsel, accountants or other advisors, as it deems appropriate, at the Company’s expense. We have engaged the compensation consulting services of Watson Wyatt and Towers Perrin in 2006. Watson Wyatt provides the Compensation Committee and management with market data on Board of Directors and executive compensation, and provides proxy statement consulting services. Towers Perrin provides the Compensation Committee and management with plan design consulting, executive compensation consulting, market surveys and compensation communications support. These consultants are regularly available at Compensation Committee meetings for presentation, discussion and questions. In accordance with the rules and regulations of the SEC and the NYSE, the Compensation Committee Report can be found on page [  ] of this Proxy Statement.
 
Nominating and Governance Committee
 
The Nominating and Governance Committee met 5 times during fiscal year 2006. The Nominating and Governance Committee is comprised of non-employee directors, all of whom meet the independence requirements of the NYSE and the SEC. As outlined in its written charter, the Nominating and Governance Committee has responsibility for recommending nominees for election and re-election to the Board, ensuring that Board nominees are qualified and consistent with our needs, monitoring significant developments in the law and practice of corporate governance for directors of public companies, recommending Board committee assignments, reviewing and recommending Board policies and procedures, monitoring compliance with our stock ownership guidelines and board service policy, and overseeing the Board and each committee of the Board in their annual performance self-evaluations. In addition, the Nominating and Governance Committee is responsible for recommending to the Board candidates for Chief Executive Officer, overseeing the annual assessment of the performance of the Chief Executive Officer and developing an ongoing succession plan for the Chief Executive Officer.


17


Table of Contents

 
The Nominating and Governance Committee is responsible for reviewing with the Board, on an annual basis, the current size, structure and composition of the Board as a whole, and whether the Company is being well served by the directors taking into account: the directors’ degree of independence; business background, including any areas of particular expertise, such as accounting or related financial management expertise, marketing or technology; record of service (for incumbent directors), including attendance record; meeting preparation; overall contribution to the Board; employment status; gender; ethnicity; age; availability for service to the Company; and anticipated needs of the Company.
 
Finance and Strategic Investment Committee
 
The Finance and Strategic Investment Committee met 5 times during fiscal year 2006. The primary role of this Committee is to provide a forum within the Board to review our overall financing plans and long-term strategic objectives, as well as our shorter-term acquisition and investment strategies and how these shorter-term activities fit within our overall business objectives. As outlined in its written charter, the Committee is charged with providing Board oversight of our strategic planning and activities, approving strategic transactions for which the Board has delegated authority, making recommendations to the Board regarding larger transactions, and evaluating our financial strategies and policies. The Committee has responsibility to review periodically with management our strategic business objectives and the manner in which transactional activity can contribute to the achievement of those objectives, and to review with management on a regular basis contemplated strategic opportunities. The Committee conducts periodic reviews of completed transactions for the purposes of assessing the degree of success achieved, testing the extent to which the projections and other assumptions relied upon in approving transactions have been borne out, identifying the factors differentiating more successful transactions from less successful ones and evaluating the strategic contributions resulting from these transactions. The Committee is further charged with conducting periodic reviews of our cash investments and cash management policies, debt ratings and global financing objectives and strategies, including the review and approval of certain borrowing arrangements, capital expenditures and dispositions, and activities that may impact our existing capital structure.
 
Compliance and Quality Committee
 
The Compliance and Quality Committee was formed in May and met 5 times during fiscal year 2006. The primary role of this Committee is to oversee and evaluate our compliance and quality control systems and initiatives, the systems in place to maintain, and identify deviations from, our compliance and control standards, and our efforts to meet or exceed our compliance and quality control standards. The Committee reviews and discusses with senior management the adequacy and effectiveness of our compliance and quality control systems and initiatives, and reviews periodic reports regarding any deviations from our standards. The Committee also reviews all correspondence from any external quality control inspectors, such as the FDA, and discusses with senior management our responses to those communications. In addition, the Committee monitors, with senior management, the progress of Project Horizon, our cross-functional effort to identify opportunities to reduce quality compliance risks, as well as the training and education programs for our employees. The Committee recommends to the Board of Directors any actions it deems necessary or appropriate to improve the effectiveness of our compliance and quality control systems and initiatives.
 
Compensation Committee Interlocks and Insider Participation
 
The members of our Executive Compensation and Human Resources Committee during 2006 were Warren B. Rudman, Ursula M. Burns, Nancy-Ann DeParle, Kristina M. Johnson and Ray J. Groves. None of these Committee members is or has ever been an officer or employee of the Company. To our knowledge, there were no other relationships involving members of the Compensation Committee or our other directors which require disclosure in this Proxy Statement as a Compensation Committee interlock.


18


Table of Contents

 
EXECUTIVE COMPENSATION
 
Compensation Discussion & Analysis
 
The following discussion and analysis contains statements regarding individual and company performance targets and goals. These targets and goals are disclosed in the limited context of our compensation programs and should not be understood to be statements of management’s future expectations or estimates of future results or other guidance. We specifically caution investors not to apply these statements to other contexts.
 
Our Executive Compensation Philosophy and Objectives
 
Our executive compensation philosophy is to provide our executives with appropriate and competitive individual pay opportunities with actual pay outcomes heavily influenced by the attainment of corporate and individual performance objectives. The objectives of our compensation program are to attract, retain, engage, focus and reward the best available talent to achieve performance goals aligned with our mission, quality policy and business goals. Our mission is to improve the quality of patient care and the productivity of healthcare delivery through the development and advocacy of less invasive medical devices and procedures. Our quality policy, applicable to all employees, is: “I improve the quality of patient care and all things Boston Scientific.” Our business goals include the achievement of specified sales, net income and quality targets.
 
How We Determine Executive Compensation
 
Our Executive Compensation and Human Resources Committee, and in certain cases our Board of Directors, bear principal responsibility for assessing, determining and approving our executive compensation. Information about our Compensation Committee and its composition, processes and responsibilities can be found on page [  ] of this proxy statement, under the heading “Executive Compensation and Human Resources Committee.” There are three key elements to our executive compensation setting process: performance considerations and business goals; market referencing; and CEO and Compensation Committee judgment.
 
Performance Considerations and Business Goals
 
We award our executives compensation and assign them additional responsibilities as recognition for how well they perform as a team in achieving our business goals, as well as their individual goal achievement. In order to determine whether our executives achieved individual and corporate goals, we conduct an annual Performance Achievement and Development Review (PADR). The PADR process is designed to guide performance discussions, clarify an executive’s performance objectives and communicate annual achievements. At the end of each year, overall performance is rated unsatisfactory to outstanding. These achievement indicators heavily influence the executive’s compensation. Our CEO conducts each Named Executive Officer’s (NEO’s) PADR and the Chairman of the Board and the Governance Committee conduct the CEO’s PADR.
 
Market Referencing
 
In addition to performance considerations, we also base our compensation decisions on market considerations. The principle of market referencing means that our compensation and benefit programs are benchmarked and administered against programs available to employees in comparable roles at peer companies. To help collect market information, we engaged the services of Towers Perrin and Watson Wyatt, third party compensation consultants, in 2006. Their assistance included helping to define a peer group of companies and then collecting relevant market data from these companies for base salary, incentive bonus and equity award referencing purposes. In late 2005, Watson Wyatt worked with management to define a 2006 peer group which is comprised of leading companies in the medical device and pharmaceutical industries. As a result of our acquisition of Guidant in early 2006, we revised our peer comparison group during the course of the year to reflect the larger revenue size of the combined Boston Scientific and Guidant entity. The initial 2006 peer group and the revised 2006 peer group are shown below. For 2007 and beyond, our Compensation Committee, with input from Watson Wyatt and management, has assumed principal responsibility for determining our peer group and plans to work with Watson Wyatt to define a new peer group for 2007 during the first half of the year.


19


Table of Contents

 
         
Initial 2006 Peer Group
 
Revised 2006 Peer Group
 
 
Baxter Health Care
    Abbott Laboratories  
Becton, Dickson & Company
    Baxter Health Care  
C.R. Bard
    Becton, Dickinson & Company  
Bristol-Myers Squibb
    Bristol-Myers Squibb  
Guidant
    Eli Lilly and Company  
Eli Lilly and Company
    Johnson & Johnson  
Medtronic
    Medtronic  
St. Jude Medical
    Schering Plough  
Stryker
    St. Jude Medical  
Wyeth Pharmaceuticals
    Stryker  
Zimmer Holdings
    Wyeth Pharmaceuticals  
 
 
In addition, as it related to the Compensation Committee’s determination of CEO compensation for 2006, Watson Wyatt conducted the following detailed analyses relative to the Initial 2006 Peer Group:
 
  •  Pay for performance:  A comparison of the relationship between (1) our CEO’s 2005 realizable pay (defined as cash compensation paid to our CEO plus his in-the-money stock option value over the past six years) and (2) 2005 Company performance (defined as total shareholder return, revenue growth and net income growth over the past five years) revealed a close correlation between our CEO’s historical pay and the Company’s performance. Relative to the Initial 2006 Peer Group, our CEO’s realizable pay and Company performance were both positioned in the 75th percentile of the peer group. However, our CEO’s pay exhibited significantly more risk than CEO pay at our peers in that his total cash compensation was positioned in the 25th percentile and his in-the-money stock option value was positioned in the 75th percentile.
 
  •  Capital accumulation and value realized:  A comparison of our CEO’s 2005 total capital accumulation (comprised of shares owned outright, outstanding stock options, and accrued retirement benefit value) relative to the Initial 2006 Peer Group revealed that our CEO was positioned in the 25th percentile of peers in terms of capital accumulation. In terms of 2005 value realized (value of in-the-money gains realized from stock option exercises), our CEO was positioned in the 75th percentile of the peer group.
 
  •  Total remuneration:  A comparison of our CEO’s 2005 total remuneration (comprised of base salary, annual bonus, long-term incentives and benefits) relative to the Initial 2006 Peer Group demonstrated that our CEO’s total remuneration fell within the 25th percentile of our peer group.
 
Towers Perrin also assisted us with market referencing by providing information from its data bank on competitive levels of executive compensation. Based in part on this information, we targeted base salaries and executive benefits at the median, Performance Incentive Plan awards at the 75th percentile and the grant value of equity awards at the 60th percentile of the Revised 2006 Peer Group. These are overall guidelines, but individual compensation pay levels may vary based on individual performance and other factors. For example, in the case of a new hire, we also consider compensation provided by the previous employer in setting initial pay levels and in making an attractive offer of employment.
 
CEO and Compensation Committee Judgment
 
Our total compensation program operates not only based on the application of Company and individual performance considerations and market referencing but also through the application of CEO and Compensation Committee judgment. We do not employ a purely formulaic approach to any of our compensation plans. There are guidelines and funding formulas in place for our incentive plan which are tied to specific financial and quality results, but there is also an individual performance factor and executive retention considerations that permit discretion to increase or decrease formula-driven awards based on those considerations. As part of our Performance


20


Table of Contents

Incentive Plan, the Compensation Committee may adjust a maximum funded or formula incentive award downward based on the executive’s individual contribution and performance.
 
In making its compensation determinations, our Compensation Committee has begun reviewing tally sheets, which provide a total of all elements of compensation for each of our executive officers. In addition, the Compensation Committee considers the economic value as well as the retentive value of prior equity grants received by our executives in determining current or future compensation, and considers each executive’s compensation compared to the compensation of other executives and other employees generally. In determining the reasonableness of our executives’ total compensation, the Compensation Committee reviews not only individual and Company performance compared to plan, but also the nature of each element of executive compensation provided, including salary, bonus, long-term incentive compensation, accumulated realized and unrealized stock option gains, and other personal benefits, as well as the terms of executive severance and change of control arrangements.
 
In addition, while the Compensation Committee is solely responsible for setting the targets and approving the awards, the Compensation Committee relies on the judgment of the CEO regarding setting executive performance objectives, evaluating the actual performance of each executive (other than the CEO) against those objectives through the PADR process and recommending appropriate salary and incentive awards. The CEO participates in Compensation Committee meetings, at the request of the Committee, in order to provide background information and explanations supporting his recommendations.
 
Our Elements of Total Executive Compensation
 
Overview of compensation.  Our total compensation program consists of fixed compensation elements, such as base salary and benefits, and variable performance-based elements, such as annual and long-term incentives. Our fixed compensation elements are designed to provide a stable source of income and financial security to our executives. Our variable performance-based compensation elements are designed to reward performance at three levels: individual performance, actual Company performance compared to annual business goals, and Company performance in terms of long-term shareholder value creation. Through these performance incentive awards, we reward the achievement of short-term goals, such as successful marketing, manufacturing and sales of products, integrations of acquired businesses, and the promotion of a culture of quality, and long-term goals, such as business growth, innovation and stock price appreciation.
 
Three primary elements of direct compensation.  We compensate our executives principally through base salary, performance-based annual incentives and annual equity awards. This three-part compensation approach enables us to remain competitive with our industry peers while ensuring that executive officers are appropriately incentivized to deliver short-term results while creating sustainable long-term stockholder value. Our Compensation Committee has chosen to put a significant portion of each executive’s pay at risk, contingent upon the achievement of certain goals within our strategic plan and within targeted market positions typically established by reference to our peer group. Each element in the program has a primary role, one or more objectives and a target market position as shown in the table below:
 
             
            Targeted Market
Element
 
Role
 
Objective
 
Position
 
Base Salary   Provide stable source of income   Attract and retain talent   Median
Performance Incentive Plan (PIP)   Reward for quarterly and annual goal achievement   Focus talent on annual goals, reward talent   75th percentile
Annual Equity Incentives   Reward for long-term business building   Focus talent on long-term shareholder value creation; retain and engage talent   60th percentile
 
Of these three elements, our total executive compensation package is heavily weighted towards the variable, performance-based elements of our Performance Incentive Plan and Annual Equity Incentives. For 2006, 83% of the total direct compensation for our NEOs as a group consisted of variable (versus fixed) compensation. Of that


21


Table of Contents

83%, 67% took the form of stock options or DSUs which are designed to reward long-term performance and 16% took the form of performance incentive awards and cash bonuses, which are designed to reward short-term performance. The remaining 17% took the form of base salary. We feel that this mix reinforces our desire to pay for actual performance.
 
Base Salary
 
Overview.  In general, the Compensation Committee targets base salaries at levels consistent with the median rate paid for equivalent positions by our peers. In addition, the Compensation Committee considers our annual merit budget, each executive’s current and prior year salary and the executive’s actual performance compared to the goals and objectives established for the executive at the beginning of the year. NEO salaries for 2006 are reported in the Summary Compensation Table on page [  ] under the Salary column.
 
NEOs (other than CEO).  We establish base salaries for our executive officers (other than the CEO) based upon the PADR performance reviews conducted by and the recommendations of the CEO presented to the Compensation Committee for approval or modification. To remain competitive in the industry and to acknowledge individual officers’ contributions and objectives in light of our Project Horizon quality system improvement initiative and business integration efforts, the Committee approved competitive base salary increases for our NEOs for 2006, as recommended by the CEO. Mr. LaViolette’s increase was, in part, attributable to a base salary adjustment based on a market comparison of his salary compared to the salaries of other chief operating officers within our peer group. In addition, Mr. Colen received a mid-year increase in recognition of his promotion in May 2006 to assume additional operations and technology responsibilities within our new cardiac rhythm management division. The range of salary increases for our NEOs (other than the CEO) for 2006 from 2005 was 5.6% to 14.4% (in the case of Mr. Colen).
 
                             
Name
  2005 Base Salary     2006 Base Salary     % Increase     Effective Date
 
Paul A. LaViolette
  $ 600,000     $ 660,000       10.0 %   12/27/05
Lawrence C. Best
  $ 625,000     $ 660,000       5.6 %   12/27/05
Fredericus A. Colen
  $ 435,000     $ 465,000       6.9 %(1)   12/27/05
Fredericus A. Colen
  $ 465,000     $ 500,000       7.5 %(2)   5/8/06
Paul W. Sandman
  $ 435,000     $ 460,000       5.7 %   12/27/05
 
 
(1) Mr. Colen received a 6.9% year-end raise.
 
(2) Mr. Colen received an additional 7.5% mid-year raise in connection with his assumption of additional responsibilities within our new cardiac rhythm management division after our Guidant acquisition.
 
CEO.  The base salary for our CEO is established by the Compensation Committee upon the recommendation of the Chairman of the Board and the Governance Committee of the Board of Directors after consideration of the CEO’s performance for the prior year. As part of its determination, the Committee reviews an assessment of the CEO’s actual performance versus objectives set for the CEO at the beginning of the year, the Company’s actual performance during the year, as well as market data provided by our compensation consultants. Our CEO’s actual base salary increase for 2006 from 2005 was 3% and became effective in late February 2006. In determining the level of the increase, the Compensation Committee considered whether the Company had met or exceeded quarterly sales and earnings targets, the performance of our TAXUS® stent system, our product development initiatives and business integrations, as well as other matters.
 
                             
Name
  2005 Base Salary     2006 Base Salary     % Increase     Effective Date
 
James R. Tobin
  $ 900,000     $ 927,000       3 %   2/28/06
 
Performance Incentives
 
Overview.  Through our Performance Incentive Plan for all salaried personnel, we seek to provide pay for performance by linking incentive awards to both Company and individual performance through a range of award opportunities which depend upon the level of achievement of quarterly Company and individual objectives. The


22


Table of Contents

Compensation Committee measures corporate achievement on a quarterly basis against sales, net income and quality objectives established prior to the beginning of the quarter to determine the size of a bonus pool. These goals excluded legacy Guidant results in 2006 because the acquisition closed during the second quarter of the year. The Compensation Committee measures individual achievement for an executive officer by comparing the actual performance of the executive to the goals and objectives established for the executive at the beginning of or during the year.
 
For the first half of the year, the relative weightings of our corporate objectives were 50% of the award based on sales and 50% based on net income (excluding certain charges). In the second half of 2006, we revised the weightings to 35% of the award based on sales, 35% based on net income (excluding certain charges), and 30% based on quality, to further emphasize our commitment to improving quality throughout the organization and the introduction of our new quality policy. Each executive’s incentive award opportunity for the year (the “target”) is expressed as a percentage of base salary. The CEO’s target is 100% of his base salary; the Chief Operating Officer’s target is 85% of his base salary; and the target for all of our other executive officers is 75% of his or her base salary.
 
We set our quarterly net income, sales and quality goals on a quarter by quarter basis. We determine the funding percentage of our Performance Incentive Plan on a quarterly basis based on actual results and the total annual funding is the sum of each quarter’s funding amount. We begin to fund for annual incentives on a quarterly basis when Company performance meets a threshold level of sales, net income or quality goals for that quarter. Funding then increases on a sliding scale (up to a maximum of 120% of target) as higher levels of sales, net income and quality goals are met, as depicted in the table below. At the end of the year, individual performance is considered pursuant to the PADR process described above and an individual performance component from 0% to 200% is applied as a multiplier at the end of the year to each executive’s funded award to obtain the executive’s final award.
 
For 2006, the performance and funding scale for our Performance Incentive Plan awards were as follows:
 
                 
    Sales and Net Income
  Quality Performance*
  Funded Award
Performance Level
 
Performance (% of Plan)
 
(% of Goals Achieved)
 
(% of Target Award)
 
Maximum
  Greater than or equal to 105%   Greater than or equal to 100%   120%
Target
  98.5-101.5%   66-85%   100%
Threshold
  90%   50-66%   50%
Zero
  Less than 90%   Less than 50%   0%
 
Effective for Q3 and Q4 only because of our mid-year decision to emphasize our commitment to quality by making it an integral part of our performance incentive program.
 
For 2006, our quarterly Performance Incentive Plan goals, excluding Guidant, were as follows:
 
                     
    Sales
    Net Income*
     
Quarter
 
($ in millions)
   
($ in millions)
   
Quality
 
First Quarter
  $ 1,587     $ 317     N/A
Second Quarter
  $ 1,622     $ 370     N/A
Third Quarter
  $ 1,582     $ 285     Run rate metrics plus training completions
Fourth Quarter
  $ 1,608     $ 243     Run rate metrics plus training completions
 
For purposes of our Performance Incentive Plan, “net income” is defined as GAAP net income excluding amounts related to the effect of purchase price allocation on assets, merger-related costs, costs associated with Guidant’s ongoing litigation, stock compensation expense and other special non-operating costs.
 
For 2006, before the application of the individual performance component of the plan, our Performance Incentive Plan funded corporate goals (excluding Guidant results) at 99.88% of target. Amounts actually awarded under our Performance Incentive Plan for 2006 are reflected in the Summary Compensation Table on page [  ] in the column Non-Equity Incentive Plan Compensation.


23


Table of Contents

 
NEOs (other than CEO).  In 2006 performance incentive awards for our NEOs (other than our CEO) ranged from 99.9% of target to 125.2% of target based on the overall performance of the Company against quarterly goals and the individual performance of each NEO during the year. Actual awards in excess of the corporate funding level of 99.88% are in recognition of significant efforts being devoted to Project Horizon, Guidant integration and business optimization, which are long-term initiatives whose expected benefits are not reflected in our current stock price, in addition to the retention challenges we face in light of recent Company stock price performance.
 
 
                         
    2006 Target Award
    2006 Actual Award
    Actual as
 
Name
  ($ in thousands)     ($ in thousands)     % of Target  
 
Paul A. LaViolette
  $ 561.0     $ 616.4       109.9%  
Lawrence C. Best
  $ 495.0     $ 494.4       99.9%  
Fredericus A. Colen
  $ 375.0     $ 469.5       125.2%  
Paul W. Sandman
  $ 345.0     $ 344.6       99.9%  
 
CEO.  In 2006, our CEO’s performance incentive award fell below his targeted payout level of $927 thousand because performance versus objectives fell below expectations. In making this determination, the Compensation Committee considered whether the Company had met certain quality, financial, business integration and product development objectives, and the performance of our TAXUS® stent system, as well as other matters.
 
 
                         
    2006 Target Award
    2006 Actual Award
    Actual as
 
Name
  ($ in thousands)     ($ in thousands)     % of Target  
 
James R. Tobin
  $ 927     $ 324.1       35 %
 
Recovery of incentive awards.  In February 2007, our Compensation Committee adopted a policy regarding the recovery or adjustment of performance incentive plan awards in the event relevant Company performance measures are restated in a manner that would have reduced a previously granted award’s size or payment. Effective for compensation awards made on or after February 20, 2007, to the extent permitted by governing law, the Board will seek reimbursement of incentive compensation paid to any executive officer in the event of a restatement of the Company’s financial results that reduced a previously granted award’s size or payment. In that event, we will seek to recover the amount of the performance incentive award paid to the executive officers which is in excess of the amounts that would have been paid based on the restated financial results.
 
Annual Equity Incentives
 
Overview.  We intend our broad-based stock option and deferred stock unit award program to attract, retain, engage and focus key employees for the long-term. The Compensation Committee approves, upon management recommendation, non-qualified stock option and deferred stock unit awards (DSUs) to eligible employees within the organization and across business units in amounts appropriate for each individual’s (i) level of responsibility, (ii) ability to affect the achievement of overall corporate objectives, (iii) individual performance, and (iv) individual potential.
 
Recent changes.  Since 2004, we have gradually changed the mix of these equity incentives from 100% options to a mix of options and DSUs. Stock options are effective in promoting shareholder alignment and holding executives accountable for generating shareholder return while DSUs are a share-efficient means for retaining top talent and promoting a long-term share owner perspective. Together, stock options and DSUs enable us to meet our dual compensation objectives of rewarding long-term goals, such as strategic growth and business innovation, and retaining top talent even during periods of significant stock price fluctuation. We have been advised by Towers Perrin that an increasing migration from stock options to DSUs or a mix of options and DSUs is a market competitive practice within our peer group. In 2007, we expect to continue to increase the use of DSUs.
 
We grant options with an exercise price equal to the fair market value based on the closing stock price on the date of grant and they typically vest over a period of three to five years. They are exercisable until the tenth anniversary of the date of grant or until the expiration of various limited time periods following termination of employment. Executive officers are prohibited from paying the exercise price for their options with promissory notes or other payment forms prohibited by the Sarbanes-Oxley Act. DSUs represent our commitment to issue


24


Table of Contents

shares to recipients after a vesting period. These awards typically vest in four equal annual installments beginning with the second anniversary of the date of grant. The slightly longer vesting period for DSUs reflects the fact that DSUs have immediate value compared to options which only have value if our stock price increases. Upon each vesting date, the DSUs are no longer subject to risk of forfeiture and shares of our common stock are issued to the recipient.
 
NEOs (other than CEO).  None of our NEOs (other than our CEO) received annual equity awards in 2006 because in 2005 we made substantial mid-year equity grants to our NEOs.
 
CEO.  In an effort to encourage our CEO to extend his tenure with us, in February 2006 the Compensation Committee awarded Mr. Tobin 250,000 DSUs, 50% of which will vest on December 31, 2008 and 50% of which will vest on December 31, 2009, contingent on his continued employment with the Company as of each of those dates, and which will be issuable to Mr. Tobin in the seventh month following the cessation of his employment with the Company. In addition, the Compensation Committee provided Mr. Tobin with an opportunity to receive up to 2,000,000 performance-based DSUs, 50% of which would be issued on December 31, 2008 in the event that shares of our common stock reach specified prices per share as set forth below and 50% of which would be issued on December 31, 2009 in the event that shares of our common stock reach specified prices per share as set forth below (units that do not vest on December 31, 2008 may vest on December 31, 2009 if the specified prices per share have been reached):
 
 
                                 
          12/31/08
    12/31/09
       
    % of Restrictions
    Measurement
    Measurement
    Total Shares
 
Share Performance Price
  that Lapse     Date     Date     Earned  
 
$75 and above
    100 %     1,000,000       1,000,000       2,000,000  
$60
    80 %     800,000       800,000       1,600,000  
$50
    60 %     600,000       600,000       1,200,000  
$40
    40 %     400,000       400,000       800,000  
$35
    20 %     200,000       200,000       400,000  
Below $35
    0 %     0       0       0  
 
As noted in the Grant of Plan-Based Awards Table on page [  ], the value of the time-vested and performance-based DSUs was $21,524,512 as of the date of grant. The current realizable value of those DSUs as of December 31, 2006 was $0. The significant difference between grant date opportunity value and current realizable value reflects the fact that vesting requirements and share price performance goals have not been met.
 
Other/Special Recognition Awards
 
In addition to the three primary elements of direct compensation described above, we periodically make special recognition awards in cash and/or stock in recognition of extraordinary achievements. For example, in May 2006, we granted special recognition bonuses to several employees, including executives, who were instrumental to the completion of the Guidant transaction. Recipients included two NEOs, Larry Best and Paul Sandman. They were permitted to receive their awards in either: (i) cash, stock options and DSUs or (ii) stock options and DSUs. Mr. Best chose to receive his award in stock options and DSUs as follows: 79,800 stock options with an exercise price of $20.60 and 27,200 DSUs. Mr. Sandman chose to receive his award in stock options, DSUs and cash as follows: 25,500 stock options with an exercise price of $20.60 and 8,700 DSUs plus cash of $400,000. The stock options will vest in equal annual installments over four years beginning May 8, 2007 and the DSUs will be issued in four equal annual installments beginning on May 8, 2008. The cash component of these awards is reflected in the Summary Compensation Table on page [  ] under the Bonus column. The equity components of these awards are reflected in the Grants of Plan-Based Awards Table on page [  ].


25


Table of Contents

In addition, in connection with the Guidant transaction, Fred Colen assumed an additional role overseeing operations and technology at our new cardiac rhythm management business. In connection with that expanded role, we increased his salary and made an award of stock options and DSUs as set forth below:
 
 
                                         
          Performance
       
          Incentive
    Long-Term
 
    Salary Increase     Opportunity     Incentive Award  
          Amount
    Percentage of
          Deferred
 
    New Salary     of Increase     Base Salary     Options     Stock Units  
 
Fred Colen
  $ 500,000     $ 35,000       75 %     130,000       45,500  
 
  Elements of Indirect Pay
 
In addition to the direct pay elements described above, we also provide our executives with indirect pay in the form of benefits.
 
General.  Our benefit program, which is available to our NEOs, is intended to provide financial protection and security for our executives and to reward them for the total commitment we expect from them in service to the Company. Our executives’ benefits program consists of three key elements: health and welfare plans based principally on a preferred provider model with the executives sharing approximately 20% of the cost; Company-paid life insurance of three times base salary (up to a $1 million benefit payable upon death); and a qualified 401(k) retirement plan with a Company match of up to 6% of base pay. Other elements include Company-paid disability benefits and the ability to participate in our Global Employee Stock Ownership Plan, which entitles employees to purchase our stock at a 15% discount. Effective July 1, 2007, the discount will be reduced from 15% to 10%.
 
Relocation.  We also have an Executive Relocation Policy for our executive officers who are requested by us to move in connection with their current job and for newly hired employees who will become executive officers of Boston Scientific and who are required to move in connection with accepting a job with us. The policy covers reasonable expenses associated with the move and certain relocation services to minimize the inconvenience of moving. None of our NEOs received any amounts under our Executive Relocation Policy during 2006.
 
Executive allowance.  Pursuant to our Executive Allowance Plan, we provide a cash allowance to eligible executives in lieu of perquisites typically provided by other companies, such as company cars, health care costs not otherwise covered or tax planning services, which we do not provide to our executives. Under this plan, our executive officers receive $25,000 per year. Amounts paid under our Executive Allowance Plan are reflected in the Summary Compensation Table on page [  ] in the column All Other Compensation.
 
401(k) Excess Benefit Plan.  In connection with a one-time special contribution we made to our 401(k) Retirement Savings Plan for the benefit of our employees announced in September 2004, we adopted in June of 2005 an Excess Benefit Plan. The Excess Benefit Plan is a non-qualified deferred compensation plan designed to provide specific supplemental benefits to those employees who would have exceeded the 2004 IRS contribution limits if the special contribution had been made to their 401(k) plan accounts. The Excess Benefit Plan was established to accept the “overflow” contributions on behalf of those employees, including our executive officers. NEO earnings during 2006 under the 401(k) Excess Benefit Plan are reflected in the Nonqualified Deferred Compensation Table on page [  ].
 
Airplane usage.  Our CEO is permitted personal use of our corporate aircraft. Other executive officers are permitted personal use of the corporate aircraft only with the prior permission of the CEO. In 2006, the only NEOs who used the corporate aircraft for personal use were Messrs. Tobin and Best. Under current IRS rules in connection with personal use of the aircraft, we impute income to the executive officer for an amount based on Standard Industry Fare Level (SIFL) rates set by the US Department of Transportation. This imputed income amount is included in an executive officer’s earnings at the end of the year and reported as W-2 income to the IRS. The IRS has set limitations on the amount we can deduct when using the SIFL method to impute income to the employee for personal use of the corporate aircraft. In 2006, $386,280 of disallowed deductions was attributable to Mr. Tobin’s personal use of the aircraft and $5,550 of disallowed deductions was attributable to Mr. Best’s personal use of the aircraft. The incremental cost of their personal use of the aircraft is reflected in the Summary Compensation Table on page [  ] in the column All Other Compensation.


26


Table of Contents

 
Tax and Accounting Considerations.
 
Tax Considerations.  Section 162(m) of the Internal Revenue Code generally disallows a tax deduction to public companies for compensation over $1 million paid to the company’s chief executive officer, chief financial officer and the three other most highly compensated executive officers. Qualifying performance-based compensation is not subject to the deduction limit if certain requirements are met. Generally, we have structured performance-based components of the compensation paid to our executive officers in a manner intended to satisfy these requirements without negatively affecting our overall compensation strategy. Our 2000 and 2003 Long-Term Incentive Plans incorporate provisions intended to comply with Section 162(m) of the Code. Incentive awards under our Performance Incentive Plan are considered performance-based awards under our Long-Term Incentive Plans, which are shareholder approved plans. For this reason, annual performance incentive amounts paid to our NEOs are not subject to the 162(m) deduction limit. For 2006, the IRS Section 162(m) limit was exceeded with respect to our CEO. Mr. Tobin received total compensation in excess of the individual $1 million limit equal to $8,031, resulting in an estimated incremental cost of $2,971 attributable to the lost corporate tax deduction.
 
We have designed our compensation programs and awards to executive officers to comply with the provisions of Section 409A of the Internal Revenue Code. For example, payments made to our executive officers under our Executive Retirement Plan are payable 181 days following the date of the executive officer’s retirement. In addition, Mr. Tobin was granted an award of 250,000 DSUs that vest on each of December 31, 2008 and December 31, 2009; however, we will not issue shares to Mr. Tobin until the seventh month following the cessation of his employment with the Company.
 
Under our Retention Agreements, we will compensate an executive for any excise tax liability he or she may incur by reason of payments made under the Retention Agreement. Our compensation consultant, Watson Wyatt, performed an analysis of the benefits that would become payable to an executive officer assuming a change in control under the Retention Agreement occurred on December 31, 2006. Based on this analysis, none of the NEOs would be assessed any excise tax liability under Section 280G of the Internal Revenue Code as a result of payments made and benefits received under the Retention Agreement.
 
Accounting Considerations.  Beginning on January 1, 2006, we began accounting for stock-based payments, including stock options and DSUs, in accordance with the requirements of FASB Statement 123(R). Beginning in July of 2007, we will decrease the employee discount under our Global Employee Stock Ownership Plan from 15% to 10% in part, because the decreased discount will result in a decreased compensation expense.
 
Our Change in Control and Post-Employment Compensation Arrangements
 
Executive retirement.  In May 2005, we adopted an Executive Retirement Plan which covers executive officers and division presidents. The Executive Retirement Plan exists to provide a clear and consistent approach to managing executive departures with a standard mutually-understood separation and post-employment relationship. The plan provides retiring executive officers with a lump sum benefit of 2.5 months of salary for each completed year of service, up to a maximum of 36 months pay. Receipt of payment is conditioned upon the retiring employee’s entering into a separation agreement with Boston Scientific, which would include a non-competition provision that protects the Company from the transfer of proprietary and business knowledge to competing companies. To be considered retired under the Executive Retirement Plan, an employee’s age plus his or her years of service with Boston Scientific must be at least 65 years (provided that the employee is at least 55 years old and has been with Boston Scientific for at least 5 years). Amounts accrued under this Plan are reflected in the Summary Compensation Table on page [  ] in the column Change in Pension Value and Nonqualified Deferred Compensation Earnings. We accrue amounts under this Plan as described in the Pension Benefits Table on page [  ] and as reflected in the Potential Payments upon Termination or Change in Control Tables beginning on page [  ].
 
Consulting arrangements.  In addition, the Executive Retirement Plan allows our CEO the discretion to cause Boston Scientific to enter into consulting arrangements with retiring executives. The purpose of these consulting arrangements is to ensure smooth executive transitions including prudent transfer of business knowledge as well as day to day project support, as needed. The consulting arrangement could provide for up to a $100,000 retainer for up to 50 days of specified consulting services and a $3,000 per diem fee thereafter for services actually rendered for the


27


Table of Contents

first year and, for future years, a $2,000 per diem fee for all services actually rendered. In 2006, we did not enter into any consulting arrangements with any of our NEOs under this Plan.
 
Executive life insurance.  We make annual payments to certain executive vice presidents following their retirement or termination (other than for cause) equal to the premium for executive life insurance (plus a gross-up amount for tax purposes) for a period ending on the tenth anniversary of the policy initiation date or, in some circumstances, such other date as would allow the policy to become self-funding. These payments represent a buyout of a former split-dollar life insurance program, which has been closed to new participants since May 2004. Three of our NEOs received executive life insurance payments (in lieu of Company-paid life insurance) in 2006 as reflected in the Summary Compensation Table on page [  ] under the column All Other Compensation. For more detail, please refer to the Potential Payments upon Termination or Change in Control Tables beginning on page [  ].
 
Retention Agreements.  Our key executives, including our NEOs, have Retention Agreements with Boston Scientific. Their purpose is to retain key executives during a potentially critical time in the event of a sale or merger of the Company. In addition, we have been advised by our compensation consultants that the terms of these agreements are market competitive within our peer group. In general, the Retention Agreements entitle key executives to a lump sum payment of three times the sum of (i) the executive’s base salary, (ii) assumed on-plan incentive bonus (or prior year’s bonus, if higher), and (iii) the annual executive allowance ($25,000), if either the executive’s employment is terminated by the Company without cause or by the executive for good reason, in each event following a change in control (a “double trigger” feature). For purposes of these agreements, “cause” generally means willfully engaging in criminal or fraudulent acts or gross misconduct that is demonstrably and materially injurious to the Company. “Good reason” generally means a meaningful alteration in position or responsibilities from those in effect prior to the change in control, a reduction in annual base salary, a relocation of more than 50 miles, a failure by the Company to continue in effect any incentive plan, a failure by the Company to provide comparable benefits, or a failure by the Company to pay any amounts owed in salary, bonus or reimbursement. The executive would also be entitled to continuation of health and other welfare benefits for three years. In addition, we would compensate the executive for any excise tax liability he or she may incur by reason of payments made under the agreement. In exchange, the executive would have confidentiality restrictions and a three-year non-solicitation obligation. In February 2007, we amended the definition of “change in control” in these agreements to mean the actual closing of a change in control transaction, rather than stockholder approval of that transaction. For more details, please refer to the Potential Payments upon Termination or Change in Control Tables beginning on page [  ].
 
Long-Term Incentive Plans.  All equity awards granted to our executive officers, including our NEOs, under our 1992, 1995, 2000 and 2003 Long-Term Incentive Plans will become immediately exercisable in the event of a “change in control” or “Covered Transaction” as defined in those Plans. Additionally, under certain circumstances in the event of a “change in control” or Covered Transaction, equity awards granted under (i) our 1992 Long-Term Incentive Plan prior to October 31, 2001 will become immediately exercisable and the value of all outstanding stock options will be cashed out, (ii) our 1995 Long-Term Incentive Plan prior to October 31, 2001 will, unless otherwise determined by our Compensation Committee, become immediately exercisable and automatically converted into an option or other award of the surviving entity, and (iii) our 2000 Long-Term Incentive Plan prior to December 2000 will become immediately exercisable and/or converted into an option or other award of the surviving entity. We have been advised by our compensation consultants that the acceleration provision of these plans are market competitive within our peer group. For more details, please refer to the Potential Payments upon Termination or Change in Control Tables beginning on page [  ].
 
Performance Incentive Plan.  Under our Performance Incentive Plan, applicable to all employees including our executive officers, participants whose employment ceases before the end of the year but who have otherwise met all plan eligibility requirements and who, as of the date they ceased employment with the Company, had attained the age of 50, accrued at least five years of service and whose age plus years of service equals or exceeds 62, may receive their performance incentive awards for the year on a prorated basis based on the percentage of the year the participant was employed by the Company and eligible to participate. For more details, please refer to the Potential Payments upon Termination or Change in Control Tables beginning on page [  ].


28


Table of Contents

 
Employee Severance Pay Plan.  All exempt employees at the director level and above, including our executive officers, are eligible for severance payments (salary and benefits continuation) equal to one month of severance pay per year of service to the Company, with a minimum benefit of 6 months pay up to a maximum of 12 months. Executives eligible for our Executive Retirement Plan are not also eligible to receive this severance benefit. For more details, please refer to the Potential Payments upon Termination or Change in Control Tables beginning on page [  ].
 
Our Equity Award Grant Practices
 
During 2006, we conducted a comprehensive internal review of our stock option grant practices from the date of our initial public offering in 1992 to the present. This review confirmed that we have not engaged in the practice of backdating our stock option exercise prices.
 
Historical Practices.  Generally, our equity award grant practices have been as follows: For non-executive employees, our Executive Vice President of Human Resources forwards recommendations regarding equity award grants to the Compensation Committee, based on input regarding individual performance she has received from divisional management. For executive officers (other than the CEO), our CEO makes those recommendations to the Compensation Committee based on his own assessment of each executive’s performance. For the CEO, our Chairman of the Board and Governance Committee makes those recommendations. We have historically granted equity awards at various times during the year for a variety of reasons, as summarized below:
 
         
Type of Grant
 
Eligibility/Purpose
 
Usual Timing (Historically)
 
Annual
  Select exempt employees (based on performance and potential)   Compensation Committee meeting held in December
Promotion
  Directors/Above (receiving promotions)   Compensation Committee meeting following date of promotion
New Hires
  Select Directors/Above (based on recruiting requirements)   Later of date of hire or approval by CEO (who has been delegated authority to make such grants by the Compensation Committee)
Special Recognition
  Select exempt employees (based on extraordinary contributions)   Compensation Committee meeting following achievement (infrequent practice)
Retention
  Select exempt employees (based on performance/potential and critical need to retain)   Compensation Committee meeting following identified need (infrequent practice)
 
Current Practices.  With respect to awards made after January 1, 2007, the Company makes annual equity awards at its February Compensation Committee meeting, in order to give the Compensation Committee the benefit of a completed year of performance prior to making grants. The February meeting typically falls during the open trading window following the release of our earnings results. In the event that the February meeting did not fall within an open window period, the equity awards would be granted as of the first business day of the next open window period. In addition, promotion, special recognition and retention awards will be granted as of the first business day of the next open window period following approval by the Compensation Committee. New hire awards for non-executive officers will continue to be approved by the CEO (pursuant to applicable equity award guidelines for each job position) under the authority delegated to him by the Compensation Committee and are effective on the later of the date of hire or the CEO’s approval. New hire awards for executive officers require approval of the Compensation Committee. All stock option awards are granted with an exercise price equal to the closing price of Company common stock on the date of grant.


29


Table of Contents

 
COMPENSATION COMMITTEE REPORT
 
The Compensation Committee of the Board of Directors of Boston Scientific has reviewed and discussed the Compensation, Discussion and Analysis contained in this Proxy Statement with management and, based on such review and discussions, the Compensation Committee recommended that the Compensation Discussion and Analysis be included in this Proxy Statement and in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 for filing with the SEC.
 
THE COMPENSATION COMMITTEE
Warren B. Rudman, Chairman
Ursula M. Burns
Nancy-Ann DeParle
Ray J. Groves
Kristina M. Johnson


30


Table of Contents

 
SUMMARY COMPENSATION TABLE
 
The table below summarizes the total compensation paid or earned by each of our NEOs for the fiscal year ended December 31, 2006.
 
                                                                         
                                        Change in
             
                                        Pension
             
                                        Value and
             
                                        Nonqualified
             
                                  Non-Equity
    Deferred
             
                      Stock
    Option
    Incentive Plan
    Compensation
    All Other
       
Name and Principal
        Salary
    Bonus
    Awards
    Awards
    Compensation
    Earnings
    Compensation
    Total
 
Position
  Year     ($)(1)     ($)(2)     ($)(3)     ($)(4)     ($)(5)     ($)(6)     ($)(7)     ($)  
 
James R. Tobin
    2006     $ 922,576       $0     $ 5,102,711     $ 1,398,787     $ 324,100     $ 300,570     $ 311,822     $ 8,360,566  
President and Chief Executive Officer
                                                                       
Lawrence C. Best
    2006     $ 660,050       $0     $ 784,098     $ 1,422,575     $ 494,400     $ 327,634     $ 51,026     $ 3,739,783  
Executive Vice President — Finance & Administration and Chief Financial Officer
                                                                       
Paul A. LaViolette
    2006     $ 660,000       $0     $ 447,556     $ 1,431,543     $ 616,400     $ 263,334     $ 144,726     $ 3,563,559  
Chief Operating Officer
                                                                       
Fredericus A. Colen
    2006     $ 488,341       $0     $ 960,206     $ 1,547,955     $ 469,500     $ 198,530     $ 108,772     $ 3,773,304  
Executive Vice President, Operations and Technology, CRM and Chief Technology Officer
                                                                       
Paul W. Sandman
    2006     $ 460,027     $ 400,000     $ 358,242     $ 938,726     $ 344,600     $ 224,265     $ 133,797     $ 2,859,657  
Executive Vice President and General Counsel
                                                                       
 
(1) The amount reflected in Mr. Tobin’s salary column reflects the prorated annual salary Mr. Tobin received in 2006 as a result of an annual base salary increase in late February 2006. In addition, the amount reflected in Mr. Colen’s salary column reflects a prorated annual salary due to an increase in Mr. Colen’s base salary in May 2006 in connection with his mid-year assumption of additional responsibilities related to our CRM division. A description of Mr. Tobin’s and Mr. Colen’s base salary increases in 2006 can be found in the Compensation Discussion and Analysis beginning on page [  ]. The amounts reflected in this column for the remaining NEOs reflect their salary for the full year.
 
(2) The amount reflected in this column represents the cash component of a special recognition bonus in connection with the consummation of the Guidant acquisition paid to Mr. Sandman in May 2006. A description of this special recognition bonus can be found under the title “Other/Special Recognition Awards” in the Compensation Discussion and Analysis beginning on page [  ].
 
(3) The amounts included in the “Stock Awards” column represent the compensation cost we recognized in 2006 related to all outstanding non-option stock awards (deferred stock units awards), as described in Statement of Financial Accounting Standards No. 123(R). For a discussion of the valuation assumptions, see Note L to our consolidated financial statements included in our annual report on Form 10-K for the year ended December 31, 2006. Please see the “Grants of Plan Based Awards Table” for more information regarding the stock awards we granted in 2006.
 
(4) The amounts included in the “Option Awards” column represent the compensation cost we recognized in 2006 related to all outstanding option stock awards, as described in Statement of Financial Accounting Standards No. 123(R). For a discussion of the valuation assumptions, see Note L to our consolidated financial statements included in our annual report on Form 10-K for the year ended December 31, 2006. Please see the “Grants of Plan Based Awards Table” for more information regarding the option awards we granted in 2006.
 
(5) Amounts reflected in this column represent cash payments for our NEOs’ 2006 performance made in February 2007 under the Boston Scientific Performance Incentive Plan.
 
(6) The amount shown for each NEO in the “Change in Pension Value and Nonqualified Deferred Compensation Earnings” column is attributable to the change in the actuarial present value of the accumulated benefit under our Executive Retirement Plan at December 31, 2006, as compared to December 31, 2005. Please see the “Pension Benefits Table” for more information regarding the accrued benefits for each NEO under this plan.


31


Table of Contents

 
(7) The amounts reflected in the “All Other Compensation” column are comprised of the following components:
 
                                                 
    Company
                               
    Match
          Personal Use
    Term Life
    Other Life
    Total
 
    (401(k)
    Executive
    of Corporate
    Insurance
    Insurance
    All Other
 
    Plan)(a)     Allowance(b)     Aircraft(c)     Premium(d)     Premium(e)     Compensation(f)  
 
James R. Tobin
  $ 13,200     $ 25,000     $ 264,265     $ 7,920           $ 311,822  
Lawrence C. Best
  $ 13,200     $ 25,000     $ 6,229     $ 5,160           $ 51,026  
Paul A. LaViolette
  $ 13,200     $ 25,000                 $ 105,872     $ 144,726  
Fredericus A. Colen
  $ 13,200     $ 25,000                 $ 60,798     $ 108,772  
Paul W. Sandman
  $ 8,800     $ 25,000                 $ 98,691     $ 133,797  
 
(a) The amounts reflected in this column represent our matching contributions allocated to each of the NEOs under our 401(k) Retirement Savings Plan. All contributions to this 401(k) Retirement Savings Plan as well as any matching contributions are fully vested upon contribution.
 
(b) We provide executive officers an executive benefits package that includes, in addition to regular employee benefits, an allowance in the amount of $25,000 in lieu of other perquisites typically paid by other companies. For additional information about our Executive Allowance Plan, see the Compensation Discussion and Analysis section titled “Executive Allowance Plan” on page [  ].
 
(c) The amounts reflected in the Personal Use of Corporate Aircraft column represent the incremental costs to us for Mr. Tobin’s and Mr. Best’s personal use of the corporate aircraft. We calculate a portion of the incremental cost to us by dividing the number of miles the corporate aircraft has flown per month by the associated monthly variable operating costs for the corporate aircraft. This dollar per mile amount is then multiplied by the number of miles flown for personal use of the aircraft during the month. Since the corporate aircraft is used predominately for business travel, we do not include the monthly fixed costs to operate the corporate aircraft, such as pilot salary, general taxes and insurance, for purposes of this incremental cost calculation. Our incremental cost does not include amounts attributable to the NEO for increased income taxes we incurred in 2006 as a result of disallowed deductions related to that personal use under IRS rules. For 2006, the reflected amounts exclude $386,280 of disallowed deduction attributable to Mr. Tobin and $5,550 attributable to Mr. Best.
 
(d) Amounts in this column represent the imputed income attributable to Mr. Tobin and Mr. Best for term life insurance.
 
(e) Amounts in this column represent amounts paid to each of the NEOs to fund premiums for universal life insurance and imputed income related to our termination of a previously established split dollar life insurance program. The amounts reflected include a gross-up amount to cover related tax obligations: $46,910 for Mr. LaViolette, $30,395 for Mr. Colen and $44,877 for Mr. Sandman.
 
(f) This column also includes incidental amounts that fall below the required disclosure thresholds.


32


Table of Contents

 
GRANTS OF PLAN BASED AWARDS
 
The table below shows each grant of an award made to an NEO under any plan during the year ended December 31, 2006.
 
                                                                                         
                                                    All Other
             
                                              All Other
    Option
             
                                              Stock
    Awards:
    Exercise
    Grant Date
 
          Estimated Future Payouts Under
                      Awards:
    Number of
    or Base
    Fair Value
 
          Non-Equity Incentive Plan
    Estimated Future Payouts Under
    Number of
    Securities
    Price of
    of Stock and
 
          Awards(1)     Equity Incentive Plan Awards     shares of
    Underlying
    Option
    Option
 
    Grant
    Threshold
    Target
    Maximum
    Threshold
    Target
    Maximum
    Stock or
    Options
    Awards
    Awards
 
Name
  Date     ($)     ($)     ($)     (#)     (#)     (#)     Units (#)(2)     (#)(2)     ($/Sh)     ($)  
 
James R. Tobin
          $ 0     $ 927,077     $ 2,224,985                                                          
      2/28/06 (3)                             200,000               2,000,000                             $ 15,419,512  
      2/28/06 (4)                                                     250,000                     $ 6,105,000  
Lawrence C. Best
          $ 0     $ 495,038     $ 1,188,091                                                          
      5/17/06 (5)                                                     27,200                     $ 560,320  
      5/17/06 (5)                                                             79,800     $ 20.60     $ 587,328  
Paul A. LaViolette
          $ 0     $ 561,000     $ 1,346,400                                                          
Fredericus A. Colen
    5/8/06 (6)   $ 0     $ 375,000     $ 900,000                               45,500                     $ 997,815  
      5/8/06 (6)                                                             130,000     $ 21.93     $ 1,017,900  
Paul W. Sandman
    5/17/06 (5)   $ 0     $ 345,020     $ 828,048                               8,700                     $ 179,220  
      5/17/06 (5)                                                             25,500     $ 20.60     $ 187,680  
 
(1) These columns reflect threshold, target and maximum payout levels under our Performance Incentive Plan for 2006 performance. The actual amount earned by each NEO is reported under the Non-Equity Incentive Plan Compensation column in the Summary Compensation Table. Additional information about our Performance Incentive Plan is included in the Compensation Discussion and Analysis section of this proxy statement beginning on page [  ].
 
(2) These columns reflect the number of deferred stock units and stock options granted under our 2003 Long-Term Incentive Plan during 2006. These awards are also described in the Outstanding Equity Awards at Fiscal Year-End Table below.
 
(3) On February 28, 2006, Mr. Tobin was awarded an opportunity to receive up to 2,000,000 performance-based deferred stock units, 50% of which would be issued on December 31, 2008 in the event that shares of our common stock reach specified prices per share as set forth below and 50% of which would be issued on December 31, 2009 in the event that shares of our common stock reach specified prices per share as set forth below (units that do not vest on December 31, 2008 may vest on December 31, 2009 if the specified prices per share have been reached):
 
                                 
    % of
    12/31/08
    12/31/09
       
    Restrictions
    Measurement
    Measurement
    Total Shares
 
Share Performance Price
  that Lapse     Date     Date     Earned  
 
$75 and above
    100 %     1,000,000       1,000,000       2,000,000  
$60
    80 %     800,000       800,000       1,600,000  
$50
    60 %     600,000       600,000       1,200,000  
$40
    40 %     400,000       400,000       800,000  
$35
    20 %     200,000       200,000       400,000  
Below $35
    0 %     0       0       0  
 
(4) On February 28, 2006, Mr. Tobin was also awarded 250,000 deferred stock units, 50% of which will vest on December 31, 2008 and 50% of which will vest on December 31, 2009, contingent on his continued employment as of each of those dates. The shares will be issued to Mr. Tobin during the seventh month following his cessation of employment with us.
 
(5) In May 2006, several employees, including Mr. Best and Mr. Sandman, received a special recognition bonus as a result of the completion of the Guidant acquisition. Mr. Best and Mr. Sandman were each awarded a specified number of stock options that vest in four equal annual installments beginning on May 17, 2007 (the first anniversary of the date of grant) and a specified number of deferred stock units that vest in four equal annual installments beginning on May 17, 2008 (the second anniversary of the date of grant). A description of this special recognition bonus can be found under the title “Other/Special Recognition Awards” in the Compensation Discussion and Analysis beginning on page [  ].
 
(6) In connection with Mr. Colen’s assumption of increased responsibilities related to our CRM division, in May 2006, he was awarded 45,500 deferred stock units that vest in four equal annual installments beginning on May 8, 2008 (the second anniversary of the date of grant) and 130,000 options to purchase our common stock that vest in four equal annual installments beginning on May 8, 2007 (the first anniversary of the date of grant).


33


Table of Contents

 
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END
 
This table shows unexercised options, stock that has not vested and equity incentive plan awards for each NEO outstanding as of December 31, 2006.
 
 
                                                                         
    Option Awards     Stock Awards  
                                                    Equity
 
                                                    Incentive
 
                                                    Plan Awards:
 
                                              Equity
    Market
 
                Equity
                            Incentive
    or Payout
 
                Incentive
                            Plan Awards:
    Value of
 
                Plan Awards:
                      Market
    Number of
    Unearned
 
                Number
                      Value of
    Unearned
    Shares,
 
    Number of
    Number of
    of Securities
                Number of
    Shares or
    Shares,
    Units or
 
    Securities
    Securities
    Underlying
                Shares or
    Units of
    Units or
    Other
 
    Underlying
    Underlying
    Unexercised
    Option
          Units of
    Stock that
    Other
    Rights
 
    Unexercised
    Unexercised
    Unearned
    Exercise
    Option
    Stock that
    Have Not
    Rights
    That Have
 
    Options (#)
    Options (#)
    Options
    Price
    Expiration
    Have Not
    Vested
    That Have
    Not Vested
 
Name
  Exercisable     Unexercisable     (#)     ($)     Date     Vested (#)     (#)(1)     Not Vested (#)     ($)(1)  
 
James R. Tobin
    2,000,000                     $ 17.00       3/17/09                                  
      180,000                     $ 14.1563       5/9/10                                  
      130,000                     $ 8.50       7/25/10                                  
      450,000                     $ 6.125       12/6/10                                  
      90,000                     $ 12.50       12/17/11                                  
      150,000       50,000 (4)           $ 21.78       2/25/13                                  
      150,000       50,000 (5)           $ 33.80       12/16/13                                  
      56,250       168,750 (6)           $ 34.29       1/3/15                                  
                                              250,000 (2)   $ 4,295,000                  
                                                              200,000 (3)   $ 3,436,000  
Lawrence C. Best
    600,000                     $ 12.4063       5/5/07                                  
      56,000                     $ 10.3907       12/19/07                                  
      1,000,000                     $ 18.7657       7/21/08                                  
      30,000                     $ 12.4375       12/13/08                                  
      40,000                     $ 17.875       4/19/09                                  
      120,000                     $ 14.1563       5/9/10                                  
      120,000                     $ 8.50       7/25/10                                  
      60,000                     $ 12.50       12/17/11                                  
      120,000                     $ 21.255       12/9/12                                  
      45,000       15,000 (9)           $ 34.79       12/11/13                                  
      15,000       45,000 (6)           $ 34.29       1/3/15                                  
              125,000 (10)           $ 26.89       7/1/15                                  
              79,800 (11)           $ 20.60       5/17/16                                  
                                              50,000 (7)   $ 859,000                  
                                              27,200 (8)   $ 467,296                  
Paul A. LaViolette
    340,000                     $ 12.4063       5/5/07                                  
      56,000                     $ 10.3907       12/19/07                                  
      30,000                     $ 12.4375       12/23/08                                  
      80,000                     $ 17.8750       4/19/09                                  
      120,000                     $ 14.1563       5/9/10                                  
      120,000                     $ 8.50       7/25/10                                  
      250,000                     $ 6.125       12/6/10                                  
      60,000                     $ 12.50       12/17/11                                  
      120,000                     $ 21.255       12/9/12                                  
      56,250       18,750 (9)           $ 34.79       12/11/13                                  
      25,000       75,000 (6)           $ 34.29       1/3/15                                  
              250,000 (10)           $ 26.89       7/1/15                                  
                                              100,000 (7)   $ 1,718,000                  


34


Table of Contents

                                                                         
    Option Awards     Stock Awards  
                                                    Equity
 
                                                    Incentive
 
                                                    Plan Awards:
 
                                              Equity
    Market
 
                Equity
                            Incentive
    or Payout
 
                Incentive
                            Plan Awards:
    Value of
 
                Plan Awards:
                      Market
    Number of
    Unearned
 
                Number
                      Value of
    Unearned
    Shares,
 
    Number of
    Number of
    of Securities
                Number of
    Shares or
    Shares,
    Units or
 
    Securities
    Securities
    Underlying
                Shares or
    Units of
    Units or
    Other
 
    Underlying
    Underlying
    Unexercised
    Option
          Units of
    Stock that
    Other
    Rights
 
    Unexercised
    Unexercised
    Unearned
    Exercise
    Option
    Stock that
    Have Not
    Rights
    That Have
 
    Options (#)
    Options (#)
    Options
    Price
    Expiration
    Have Not
    Vested
    That Have
    Not Vested
 
Name
  Exercisable     Unexercisable     (#)     ($)     Date     Vested (#)     (#)(1)     Not Vested (#)     ($)(1)  
 
Fredericus A. Colen
    10,000                     $ 7.9050       2/27/11                                  
      25,000                     $ 8.99       7/17/11                                  
      28,174                     $ 12.50       12/17/11                                  
      120,000                     $ 21.255       12/9/12                                  
      45,000       15,000 (9)           $ 34.79       12/11/13                                  
      15,000       45,000 (6)           $ 34.29       1/3/15                                  
              100,000 (10)           $ 26.89       7/1/15                                  
              130,000 (12)           $ 21.93       5/8/16                                  
                                              40,000 (7)   $ 687,200                  
                                              45,500 (13)   $ 781,690                  
Paul W. Sandman
    320,000                     $ 12.4063       5/5/07                                  
      30,000                     $ 12.4375       12/23/08                                  
      40,000                     $ 17.875       4/19/09                                  
      100,000                     $ 14.1563       5/9/10                                  
      25,000                     $ 8.50       7/25/10                                  
      50,000                     $ 12.50       12/17/11                                  
      120,000                     $ 21.255       12/9/12                                  
      45,000       15,000 (9)           $ 34.79       12/11/13                                  
      15,000       45,000 (6)           $ 34.29       1/3/15                                  
              100,000 (10)           $ 26.89       7/1/15                                  
              25,500 (11)           $ 20.60       5/17/16                                  
                                              40,000 (7)   $ 687,200                  
                                              8,700 (8)   $ 149,466                  
 
(1) The amounts reflected as Market Payout Value are based on the closing price of our common stock ($17.18) on December 29, 2006, the last business day of 2006, as reported on the New York Stock Exchange.
 
(2) Mr. Tobin was awarded 250,000 deferred stock units, 50% of which will vest on December 31, 2008, and 50% of which will vest on December 31, 2009, contingent on his continued employment as of each of those dates. The shares will be issued to Mr. Tobin during the seventh month following cessation of his employment with us. See further description of this award in the “Grants of Plan Based Awards” table above and the Compensation Discussion and Analysis beginning on page [  ].
 
(3) Mr. Tobin was awarded an opportunity to receive up to 2,000,000 performance-based deferred stock units that will vest in equal installments on each of December 31, 2008 and 2009, provided certain performance conditions have been satisfied. In accordance with SEC rules, the number of unearned shares represents the lowest award level which has not yet been earned. The number of shares reflected in this column reflects the threshold award level since the minimum performance condition has not yet been satisfied. See further description of this award in the “Grants of Plan Based Awards” table above and the Compensation Discussion and Analysis beginning on page [  ].
 
(4) These stock options vested on February 25, 2007.
 
(5) These stock options will vest on December 16, 2007.
 
(6) These stock options vest in three equal annual installments beginning on January 3, 2007.
 
(7) These deferred stock units vest in five equal annual installments beginning on July 1, 2007 (the second anniversary of the date of the award).
 
(8) These deferred stock units vest in four equal annual installments beginning on May 17, 2007 (the second anniversary of the date of the award).
 
(9) These stock options will vest on December 11, 2007.
 
(10) These stock options will vest in five equal annual installments beginning on July 1, 2007 (the second anniversary of the grant date).
 
(11) These stock options will vest in four equal annual installments beginning on May 17, 2007 (the first anniversary of the grant date).
 
(12) These stock options will vest in four equal annual installments beginning on May 8, 2007 (the first anniversary of the grant date).
 
(13) These deferred stock units will vest in four equal annual installments beginning on May 8, 2008 (the second anniversary of the date of the award).


35


Table of Contents

 
OPTION EXERCISES AND STOCK VESTED
 
None of our NEOs exercised any stock options or had any shares of stock vest during the year ended December 31, 2006.
 
PENSION BENEFITS
 
The table below shows the present value of accumulated benefits payable to each of our NEOs, including the number of years of services credited to each NEO, under our Executive Retirement Plan as of December 31, 2006.
 
 
                             
        Number of Years of
    Present Value of
    Payments During
 
        Credited Service
    Accumulated
    Last Fiscal Year
 
Name
  Plan Name (1)   (#)(2)     Benefits ($)(3)(4)     ($)  
 
James R. Tobin
  BSC Executive Retirement Plan     7.79     $ 1,504,568     $ 0  
Lawrence C. Best
  BSC Executive Retirement Plan     14.42     $ 1,980,149     $ 0  
Paul A. LaViolette
  BSC Executive Retirement Plan     12.96     $ 1,274,165     $ 0  
Fredericus A Colen
  BSC Executive Retirement Plan     7.38     $ 687,439     $ 0  
Paul W. Sandman
  BSC Executive Retirement Plan     13.67     $ 1,310,118     $ 0  
 
 
(1) We maintain an Executive Retirement Plan which covers executive officers. The plan provides retiring executive officers with a lump sum benefit (payable on the 181st day following retirement) equal to 2.5 months of salary for each completed year of service, up to a maximum of 36 months. Participants may retire with unreduced benefits once the retirement conditions have been satisfied. Mr. Tobin, Mr. Best and Mr. Sandman are currently eligible for retirement under the plan. For further discussion of our Executive Retirement Plan, please refer to the Compensation Discussion and Analysis beginning on page [  ].
 
(2) The number of years of credited service reflect the NEO’s actual service with us. We do not credit additional years of service under the plan. Rather, the plan provides that the number of years of credited service is calculated through the executive officer’s last day worked. Partially completed years of service will be pro-rated based on calendar days, and calculated to the second decimal point.
 
(3) The amounts reflected in this column represent the benefit the NEO has accrued based upon his salary and the number of years of credited service as of December 31, 2006.
 
(4) The amounts attributable to Mr. LaViolette and Mr. Colen in this column have been discounted from the earliest retirement age to December 31, 2006, using a discount rate of 5.75%. Mr. LaViolette and Mr. Colen are not currently entitled to receive these benefits because they have not met the 55 years of age threshold for retirement under this plan.
 
NONQUALIFIED DEFERRED COMPENSATION
 
The table below shows aggregate earnings and balances for each of our NEOs under our 401(k) Excess Benefit Plan as of December 31, 2006.
 
 
                                         
    Executive
    Registrant
                   
    Contributions
    Contributions
    Aggregate
    Aggregate
    Aggregate
 
    in the Last
    in the Last
    Earnings in
    Withdrawals/
    Balance at Last
 
    Fiscal Year
    Fiscal Year
    Last Fiscal
    Distributions
    Fiscal Year End
 
Name
  ($)     ($)     Year ($)(1)     ($)     ($)  
 
James R. Tobin
              $ 2,536           $ 18,746  
Lawrence C. Best
              $ 3,454           $ 25,536  
Paul A. LaViolette
              $ 3,454           $ 25,536  
Fredericus A. Colen
              $ 1,748           $ 15,260  
Paul W. Sandman
              $ 3,872           $ 26,103  
 
 
(1) We have a 401(k) Excess Benefit Plan, which is a non-qualified deferred compensation plan for executive officers. The amounts reflected in this column represent earnings during 2006 under our 401(k) Excess Benefit Plan as a result of our one-time special
401(k) contribution in 2004. The amounts are not included in the Summary Compensation Table under the column titled “Change in Pension Value and Nonqualified Deferred Compensation Earnings” since the earnings were neither above market nor preferential. Our Excess Benefit Plan is generally a mirror of our 401(k) Retirement Savings Plan in terms of investment choices except that executive officers may not elect the BSC Stock Fund or the Vanguard Retirement Savings Trust as investment vehicles under this plan. The investment elections are made by each individual participant and may be changed on a daily basis. A lump sum cash payment is available to the participant only upon retirement or termination of employment. Distributions to participants are made within six months following retirement or termination of employment. For a further description of our 401(k) Excess Benefit Plan, see the section titled “401(k) Excess Benefit Plan” in the Compensation Discussion and Analysis beginning on page [  ].
 


36


Table of Contents

 
POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL
 
The following tables show potential payments to our NEOs under existing agreements, plans or other arrangements, for various scenarios involving a change in control or termination of employment of each of our NEOs, assuming the termination date to be December 31, 2006, and where applicable using the closing price of our common stock of $17.18 (as reported on the New York Stock Exchange on December 29, 2006, the last trading day of the year).
 
 
James R. Tobin
 
                                                         
                Involuntary
    Termination
                   
          Voluntary
    Termination
    Following
                   
    Termination
    Termination
    without
    Change in
                   
    For Cause(1)     (2)     Cause(3)     Control(4)     Disability     Death     Retirement  
 
PAYMENTS DUE UPON TERMINATION:
                                                       
Cash Severance
                                                       
Base Salary
  $ 0     $ 0     $ 0     $ 2,781,231     $ 0     $ 0     $ 0  
Bonus
  $ 0     $ 0     $ 0     $ 2,781,231     $ 0     $ 0     $ 0  
Pro-rata Target Bonus(5)
  $ 0     $ 927,077     $ 927,077     $ 927,077     $ 927,077     $ 927,077     $ 927,077  
                                                         
Total Cash Severance
  $ 0     $ 927,077     $ 927,077     $ 6,489,539     $ 927,077     $ 927,077     $ 927,077  
Benefits & Perquisites
                          $ 0                          
Executive Retirement Plan(6)
  $ 0     $ 1,504,568     $ 1,504,568     $ 1,504,568     $ 0     $ 1,504,568     $ 1,504,568  
Severance Pay Plan(7)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Health and Welfare Benefits
  $ 0     $ 0     $ 0     $ 34,718     $ 0     $ 0     $ 0  
Post-Termination Life Insurance
  $ 0     $ 0     $ 0     $ 2,880     $ 0     $ 0     $ 0  
Executive Allowance
  $ 0     $ 0     $ 0     $ 75,000     $ 0     $ 0     $ 0  
Executive Life Payment(8)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Total Benefits & Perquisites
  $ 0     $ 1,504,568     $ 1,504,568     $ 1,617,166     $ 0     $ 1,504,568     $ 1,504,568  
280G Tax Gross-Up
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Long-Term Incentives
                                                       
Value of Accelerated Stock Options(9)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Value of Accelerated Deferred Stock Units(10)
  $ 0     $ 0     $ 0     $ 4,295,000     $ 4,295,000     $ 4,295,000     $ 0  
Value of Accelerated Performance Shares(11)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                         
Total Value of Accelerated Equity Grants
  $ 0     $ 0     $ 0     $ 4,295,000     $ 4,295,000     $ 4,295,000     $ 0  
Total Value: All Benefits
  $ 0     $ 2,431,645     $ 2,431,645     $ 12,401,705     $ 5,222,077     $ 6,726,645     $ 2,431,645  


37


Table of Contents

 
Lawrence C. Best
 
                                                         
                Involuntary
    Termination
                   
    Termination
          Termination
    Following
                   
    For
    Voluntary
    without
    Change in
                   
    Cause(1)     Termination(2)     Cause(3)     Control(4)     Disability     Death     Retirement  
 
PAYMENTS DUE UPON TERMINATION:
                                                       
Cash Severance
                                                       
Base Salary
  $ 0     $ 0     $ 0     $ 1,980,150     $ 0     $ 0     $ 0  
Bonus
  $ 0     $ 0     $ 0     $ 1,485,113     $ 0     $ 0     $ 0  
Pro-rata Target Bonus(5)
  $ 0     $ 495,038     $ 495,038     $ 495,038     $ 495,038     $ 495,038     $ 495,038  
                                                         
Total Cash Severance
  $ 0     $ 495,038     $ 495,038     $ 3,960,301     $ 495,038     $ 495,038     $ 495,038  
Benefits & Perquisites
                                                       
Executive Retirement Plan(6)
  $ 0     $ 1,980,149     $ 1,980,149     $ 1,980,149     $ 0     $ 1,980,149     $ 1,980,149  
Severance Pay Plan(7)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Health and Welfare Benefits
  $ 0     $ 0     $ 0     $ 45,181     $ 0     $ 0     $ 0  
Post-Termination Life Insurance
  $ 0     $ 0     $ 0     $ 2,880     $ 0     $ 0     $ 0  
Executive Allowance
  $ 0     $ 0     $ 0     $ 75,000     $ 0     $ 0     $ 0  
Executive Life Payment(8)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                         
Total Benefits & Perquisites
  $ 0     $ 1,980,149     $ 1,980,149     $ 2,103,210     $ 0     $ 1,980,149     $ 1,980,149  
280G Tax Gross-Up
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Long-Term Incentives
                                                       
Value of Accelerated Stock Options(9)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Value of Accelerated Deferred Stock Units (10)
  $ 0     $ 1,042,826     $ 1,042,826     $ 1,326,296     $ 1,326,296     $ 1,326,296     $ 1,042,826  
Value of Accelerated Performance Shares
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                         
Total Value of Accelerated Equity Grants
  $ 0     $ 1,042,826     $ 1,042,826     $ 1,326,296     $ 1,326,296     $ 1,326,296     $ 1,042,826  
Total Value: All Benefits
  $ 0     $ 3,518,013     $ 3,518,013     $ 7,389,807     $ 1,821,333     $ 3,801,483     $ 3,518,013  


38


Table of Contents

 
Paul A. LaViolette
 
                                                         
                Involuntary
    Termination
                   
    Termination
          Termination
    Following
                   
    For
    Voluntary
    without
    Change in
                   
    Cause(1)     Termination(2)     Cause(3)     Control(4)     Disability     Death     Retirement  
 
PAYMENTS DUE UPON TERMINATION:
                                                       
Cash Severance
                                                       
Base Salary
  $ 0     $ 0     $ 0     $ 1,980,000     $ 0     $ 0     $ 0  
Bonus
  $ 0     $ 0     $ 0     $ 1,683,000     $ 0     $ 0     $ 0  
Pro-rata Target Bonus(5)
  $ 0     $ 0     $ 0     $ 561,000     $ 561,000     $ 561,000     $ 0  
                                                         
Total Cash Severance
  $ 0     $ 0     $ 0     $ 4,224,000     $ 561,000     $ 561,000     $ 0  
Benefits & Perquisites
                                                       
Executive Retirement Plan(6)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Severance Pay Plan(7)
  $ 0     $ 0     $ 660,000     $ 0     $ 0     $ 0     $ 0  
Health and Welfare Benefits
  $ 0     $ 0     $ 15,369     $ 46,107     $ 0     $ 0     $ 0  
Post-Termination Life Insurance
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Executive Allowance
  $ 0     $ 0     $ 0     $ 75,000     $ 0     $ 0     $ 0  
Executive Life Payment(8)
  $ 0     $ 96,467     $ 96,467     $ 96,467     $ 96,467     $ 0     $ 96,467  
                                                         
Total Benefits & Perquisites
  $ 0     $ 96,467     $ 771,836     $ 217,574     $ 96,467     $ 0     $ 96,467  
280G Tax Gross-Up
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Long-Term Incentives
                                                       
Value of Accelerated Stock Options(9)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Value of Accelerated Deferred Stock Units(10)
  $ 0     $ 0     $ 0     $ 1,718,000     $ 1,718,000     $ 1,718,000     $ 0  
Value of Accelerated Performance Shares
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                         
Total Value of Accelerated Equity Grants
  $ 0     $ 0     $ 0     $ 1,718,000     $ 1,718,000     $ 1,718,000     $ 0  
Total Value: All Benefits
  $ 0     $ 96,467     $ 771,836     $ 6,159,574     $ 2,375,467     $ 2,279,000     $ 96,467  


39


Table of Contents

 
Fredericus A. Colen
 
                                                         
                Involuntary
    Termination
                   
    Termination
          Termination
    Following
                   
    For
    Voluntary
    without
    Change in
                   
    Cause(1)     Termination(2)     Cause(3)     Control(4)     Disability     Death     Retirement  
 
PAYMENTS DUE UPON TERMINATION:
                                                       
Cash Severance
                                                       
Base Salary
  $ 0     $ 0     $ 0     $ 1,500,033     $ 0     $ 0     $ 0  
Bonus
  $ 0     $ 0     $ 0     $ 1,125,025     $ 0     $ 0     $ 0  
Pro-rata Target Bonus(5)
  $ 0     $ 0     $ 0     $ 375,008     $ 375,008     $ 375,008     $ 0  
                                                         
Total Cash Severance
  $ 0     $ 0     $ 0     $ 3,000,066     $ 375,008     $ 375,008     $ 0  
Benefits & Perquisites
                                                       
Executive Retirement Plan(6)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Severance Pay Plan(7)
  $ 0     $ 0     $ 291,673     $ 0     $ 0     $ 0     $ 0  
Health and Welfare Benefits
  $ 0     $ 0     $ 11,573     $ 34,718     $ 0     $ 0     $ 0  
Post-Termination Life Insurance
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Executive Allowance
  $ 0     $ 0     $ 0     $ 75,000     $ 0     $ 0     $ 0  
Executive Life Payment(8)
  $ 0     $ 58,029     $ 58,029     $ 58,029     $ 58,029     $ 0     $ 58,029  
                                                         
Total Benefits & Perquisites
  $ 0     $ 58,029     $ 361,275     $ 167,747     $ 58,029     $ 0     $ 58,029  
280G Tax Gross-Up
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Long-Term Incentives
                                                       
Value of Accelerated Stock Options(9)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Value of Accelerated Deferred Stock Units(10)
  $ 0     $ 0     $ 0     $ 1,468,890     $ 1,468,890     $ 1,468,890     $ 0  
Value of Accelerated Performance Shares
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                         
Total Value of Accelerated Equity Grants
  $ 0     $ 0     $ 0     $ 1,468,890     $ 1,468,890     $ 1,468,890     $ 0  
Total Value: All Benefits
  $ 0     $ 58,029     $ 361,275     $ 4,636,703     $ 1,901,927     $ 1,843,898     $ 58,029  


40


Table of Contents

 
Paul W. Sandman
 
                                                         
                Involuntary
    Termination
                   
          Voluntary
    Termination
    Following
                   
    Termination
    Termination
    Without
    Change in
                   
    For Cause(1)     (2)     Cause (3)     Control(4)     Disability     Death     Retirement  
 
PAYMENTS DUE UPON TERMINATION:
                                                       
Cash Severance
                                                       
Base Salary
  $ 0     $ 0     $ 0     $ 1,380,081     $ 0     $ 0     $ 0  
Bonus
  $ 0     $ 0     $ 0     $ 1,035,061     $ 0     $ 0     $ 0  
Pro-rata Target Bonus(5)
  $ 0     $ 345,020     $ 345,020     $ 345,020     $ 345,020     $ 345,020     $ 345,020  
                                                         
Total Cash Severance
  $ 0     $ 345,020     $ 345,020     $ 2,760,162     $ 345,020     $ 345,020     $ 345,020  
Benefits & Perquisites
                                                       
Executive Retirement Plan(6)
  $ 0     $ 1,310,118     $ 1,310,118     $ 1,310,118     $ 0     $ 1,310,118     $ 1,310,118  
Severance Pay Plan(7)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Health and Welfare Benefits
  $ 0     $ 0     $ 0     $ 46,107     $ 0     $ 0     $ 0  
Post-Termination Life Insurance
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Executive Allowance
  $ 0     $ 0     $ 0     $ 75,000     $ 0     $ 0     $ 0  
Executive Life Payment(8)
  $ 0     $ 82,600     $ 82,600     $ 82,600     $ 82,600     $ 0     $ 82,600  
                                                         
Total Benefits & Perquisites
  $ 0     $ 1,392,718     $ 1,392,718     $ 1,513,825     $ 82,600     $ 1,310,118     $ 1,392,718  
280G Tax Gross-Up
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Long-Term Incentives
                                                       
Value of Accelerated Stock Options(9)
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Value of Accelerated Deferred Stock Units(10)
  $ 0     $ 0     $ 0     $ 836,666     $ 836,666     $ 836,666     $ 609,890  
Value of Accelerated Performance Shares
  $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                         
Total Value of Accelerated Equity Grants
  $ 0     $ 0     $ 0     $ 836,666     $ 836,666     $ 836,666     $ 609,890  
Total Value: All Benefits
  $ 0     $ 1,737,738     $ 1,737,738     $ 5,110,653     $ 1,264,286     $ 2,491,804     $ 2,347,628  
 
 
(1) Employees, including executive officers, are not entitled to any benefits upon termination for Cause. All unvested stock options and deferred stock units will be forfeited as of the date of termination, and any vested but unexercised stock options will also be forfeited upon the date of termination.
 
(2) Amounts reflected in this column represent benefits payable to the NEO upon the voluntary termination of a NEO.
 
(3) Amounts reflected in this column represent benefits payable to the NEO upon the involuntary termination of a NEO other than termination for Cause or termination resulting from a Change in Control.
 
(4) Amounts reflected in this column represent benefits payable under our Retention Agreements. For a further description of our Retention Agreements, see the Compensation Discussion and Analysis beginning on page [  ].
 
(5) Amounts reflected in the Pro-Rata Target Bonus row represent amounts earned and accrued under our Performance Incentive Plan. Under our plan, these amounts will be paid on a pro-rated basis through the date of termination, disability, death or retirement. For a further description of our Performance Incentive Plan, see the Compensation Discussion and Analysis beginning on page [  ].
 
(6) Amounts reflected in the Executive Retirement Plan row represent amounts earned under our Executive Retirement Plan, provided the NEO has reached the age of retirement under the plan (the sum of the executive officer’s age and years of service equal 65, provided the executive officer is at least 55 years old and has completed at least 5 years of service with the Company). For a further description of our Executive Retirement Plan, see the Compensation Discussion and Analysis beginning on page [  ].
 
(7) Amounts reflected in the Severance Pay Plan row represent amounts the NEO would be entitled to receive under the Boston Scientific Severance Pay Plan. For a further description of our Severance Pay Plan, please refer to the Compensation Discussion and Analysis beginning on page [  ].
 
(8) The amounts reflected in the Executive Life Payment row represent amounts the NEO is entitled to receive for Executive Life Insurance in lieu of Company-paid life insurance including a gross-up amount to cover related tax obligations. These payments continue to the earlier of death or a specified number of years. The annual premium, the amount of gross-up related to tax obligations and the number of years remaining under each policy are listed below:
 
                         
Name
 
Annual Premium
   
2006 Tax Gross-Up
   
Remaining Years under Universal Life Policy
 
 
Paul LaViolette
  $ 49,557     $ 46,910       15  
Fredericus A. Colen
  $ 27,634     $ 30,395       11  
Paul W. Sandman
  $ 37,723     $ 44,877       5  
 
(9) The amounts related to acceleration of stock options represent the value of unvested and accelerated in-the-money stock options as of December 31, 2006. At December 31, 2006, the NEOs do not have any in-the-money unvested stock options. Vested stock options would remain exercisable under the same conditions as all other participants in our equity program.
 
(10) The amounts related to acceleration of deferred stock units represent the value of the number of accelerated deferred stock units as of December 31, 2006, calculated by multiplying the number of accelerated deferred stock units by the closing price of our common stock on December 29, 2006.
 
(11) In the event of termination resulting from Disability, Death, Involuntary Termination without Cause or Termination Following a Change in Control, the number of shares to be issued to Mr. Tobin at that time under his performance share award will be determined in accordance with the performance criteria described in the Compensation Discussion and Analysis beginning on page [  ].


41


Table of Contents

 
EQUITY COMPENSATION PLANS
 
The following table summarizes information, as of December 31, 2006, relating to our equity compensation plans pursuant to which grants of options, restricted stock grants or other rights to acquire shares may be granted from time to time.
 
                         
                Number of
 
    Number of
          Securities Remaining
 
    Securities to Be
          Available for Future
 
    Issued upon Exercise
    Weighted Average
    Issuance under Equity
 
    of Outstanding
    Exercise Price of
    Compensation Plans
 
    Options,
    Outstanding Options,
    (Excluding Securities
 
    Warrants and Rights
    Warrants and Rights
    Reflected in Column (a))
 
Plan Category
  (a)     (b)     (c)  
 
Equity compensation plans approved by security holders(1)
    61,879,504     $ 20.27 (2)     42,052,732  
Equity compensation plans not approved by security holders(3)
    0     $ 0       0  
                         
Total
    61,879,504     $ 20.27 (2)     42,052,732  
                         
 
 
(1) Amounts include outstanding options under our 1992, 1995, 2000 and 2003 Long-Term Incentive Plans and our 1992 Non-Employee Directors’ Stock Option Plan. The amount in column (c) includes 18,904,551 shares available for purchase by employees under our Global Employee Stock Ownership Plan, which are not available for grant in any other form. Our 1992 Long-Term Incentive and 1992 Non-Employee Directors’ Stock Option Plans expired on March 31, 2002 and our 1995 Long-Term Incentive Plan expired on May 9, 2005, after which time grants were only issued under our 2000 and 2003 Long-Term Incentive Plans. Amounts in column (a) also include 9,875,069 shares awarded under our 2000 and 2003 Long-Term Incentive Plans in the form of deferred stock units and restricted stock.
 
(2) This weighted average exercise price does not include outstanding deferred stock units and restricted stock.
 
(3) We have acquired a number of companies over the past several years, including Guidant Corporation in 2006. From time to time, we have assumed the acquired company’s incentive plan(s), including the outstanding options and warrants, if any, granted under the plan(s). No further options are granted under these plans beyond those assumed in connection with the acquisitions. Assumed options that terminate prior to expiration are not available for re-grant. As of December 31, 2006, the aggregate number of shares to be issued under these assumed plans totaled 31,026,316. The weighted average exercise price of these options is $13.79.


42


Table of Contents

 
DIRECTOR COMPENSATION
 
We use a combination of cash and equity inventive compensation to compensate our non-employee directors. To determine the appropriate level of compensation, we rely on the consulting services of Watson Wyatt and publicly available data describing director compensation in peer companies. We also take into consideration the significant amount of time and dedication required by the directors to fulfill their duties on our Board and Board committees as well as the need to continue to attract highly qualified candidates to serve on our Board. In 2006, we adjusted our director compensation as follows:
 
Non-employee Directors.  We compensate our non-employee directors (other than the Chairman of the Board) as follows:
 
  •  An annual retainer of $60,000;
 
  •  An annual grant of the number of shares of restricted stock determined by dividing $80,000 by the fair market value of our stock on the date of grant;
 
  •  An annual fee of $20,000 for the Chair of the Audit Committee; and
 
  •  An annual fee of $10,000 for each Chair of committees other than the Audit Committee.
 
For 2006, the restricted stock awards were made as of July 25, 2006, but will be made as of the date of our annual meeting thereafter (or, if a director is elected to the Board on a date other than the annual meeting, on that date the director is first elected to the Board).
 
Employee Directors.  Directors who are also employees of the Company receive no additional compensation for serving on the Board or its committees.
 
Chairman of the Board.  Our Chairman of the Board receives an annual retainer of $210,000 and an annual grant of the number of shares of our restricted stock determined by dividing $120,000 by the fair market value of our stock on the date of grant.
 
In addition, we pay or reimburse our directors for transportation, hotel, food and other incidental expenses incurred in connection with attending Board and committee meetings and participating in director education programs.
 
We grant restricted stock awards to our non-employee directors at no charge, but they are subject to forfeiture restrictions. The shares become free from restriction upon the expiration of each director’s current term of office. The annual option grant and restricted stock awards are generally made on the date of each Annual Meeting, but if a director is elected to the Board on a date other than the Annual Meeting, a restricted stock award may be made on the date the director is first elected to the Board.
 
Non-employee directors may, by written election, defer receipt of all or a portion of the annual cash retainer, committee chair fees and the restricted stock award under our Deferred Compensation Program until he or she retires from our Board. Cash amounts deferred can be invested in common stock equivalents or another investment option in which we credit the amount deferred, plus accrued interest (compounded annually based upon the Moody’s Composite Yield on Seasoned Corporate Bonds as reported for the month of September of each calendar year). Amounts are only payable after a director’s termination of Board service, and may be either paid as a lump sum or in installments previously specified by the director at the time of election.
 
Stock ownership guidelines for directors.  All of our directors are required to have a significant personal investment in the Company through their ownership of our shares. As a guideline, each director should own at least 6,000 shares of our common stock within three years of his or her joining the Board. For purposes of satisfying this obligation, restricted stock, stock equivalent units or stock unit deferrals under our Deferred Compensation Plan may be included in the aggregate number of shares held by a director. All of our directors either currently meet our director stock ownership guidelines or we expect that they will meet the guidelines within three years of becoming a director.


43


Table of Contents

 
DIRECTOR COMPENSATION IN FISCAL 2006
 
The table below summarizes the compensation we paid to our non-employee directors for the year ended December 31, 2006.
 
                                         
    Fees Earned
          Option
             
    or Paid in
    Stock Awards
    Awards
    All Other
       
Name (1)
  Cash ($)(3)     ($)(4)     ($)(5)     Compensation($)(6)     Total ($)  
 
John E. Abele
  $ 60,000     $ 101,195     $ 8,802     $ 1,214,165     $ 1,384,162  
Ursula M. Burns
  $ 66,250     $ 90,801     $ 15,509     $ 0     $ 172,560  
Nancy-Ann DeParle(2)
  $ 45,000     $ 19,391     $ 0     $ 0     $ 64,391  
Joel L. Fleishman
  $ 80,000     $ 126,001     $ 15,509     $ 0     $ 221,510  
Marye Anne Fox
  $ 60,000     $ 135,953     $ 15,509     $ 0     $ 211,462  
Ray J. Groves
  $ 67,500     $ 99,836     $ 15,509     $ 0     $ 182,845  
Kristina M. Johnson(2)
  $ 45,000     $ 11,617     $ 0     $ 0     $ 56,617  
Ernest Mario
  $ 67,500     $ 126,001     $ 15,509     $ 0     $ 209,010  
N.J. Nicholas, Jr. 
  $ 60,000     $ 135,953     $ 15,509     $ 0     $ 211,462  
Pete M. Nicholas
  $ 210,000     $ 149,754     $ 13,203     $ 1,436,448     $ 1,809,405  
John E. Pepper
  $ 60,000     $ 135,953     $ 15,509     $ 0     $ 211,462  
Uwe E. Reinhardt
  $ 60,000     $ 126,001     $ 15,509     $ 0     $ 201,510  
Warren B. Rudman
  $ 80,000     $ 99,836     $ 15,509     $ 0     $ 195,345  
 
 
(1) James R. Tobin, a director and our President and Chief Executive Officer, is an employee and is not included in this table. Mr. Tobin’s compensation is discussed in our Compensation Discussion and Analysis beginning on page [  ] and is included in the Summary Compensation Table beginning on page [  ].
 
(2) Ms. DeParle and Ms. Johnson were elected as directors in May 2006.
 
(3) The following non-employee directors elected to defer all or a portion of their 2006 annual cash retainers in the form of common stock equivalent units in accordance with our Deferred Compensation Plan available to non-employee directors:
 
                 
    2006 Cash
    Common Stock
 
Name
  Deferred     Equivalent Units  
 
Ursula M. Burns
  $ 66,250       3,514  
Marye Anne Fox
  $ 30,000       1,572  
Ray J. Groves
  $ 67,500       3,564  
Kristina M. Johnson
  $ 11,250       636  
Ernest Mario
  $ 67,500       3,564  
N.J. Nicholas, Jr. 
  $ 60,000       3,143  
John E. Pepper
  $ 60,000       3,143  
Warren B. Rudman
  $ 75,000       3,985  
 
In addition, Marye Anne Fox elected to defer a portion of her 2006 cash retainer under the Moody’s investment option provided under the Deferred Compensation Plan.


44


Table of Contents

 
(4) Under our director compensation program, each non-employee director, except the Chairman of the Board, was granted a restricted stock award on July 25, 2006 in an amount of shares equal to the grant date fair value of $80,000, or 4,782 shares. Our Chairman of the Board was also granted a restricted stock award on July 25, 2006 in an amount of shares equal to the grant date fair value of $120,000, or 7,173 shares. The restricted stock awards vest upon the expiration of each director’s current term of office. The amounts reflected in this column represent the amount of expense we recognized for each of the director’s awards.
 
The aggregate total number of outstanding restricted awards is shown below:
 
                         
Name
  Grant Date     Number of Shares     Vesting Date  
 
John E. Abele
    7/25/06       4,782       May 2009  
Ursula M. Burns
    5/11/04       2,000       May 8, 2007  
      5/10/05       2,000       May 8, 2007  
      7/25/06       4,782       May 8, 2007  
Nancy-Ann DeParle
    7/25/06       4,782       May 2008  
Joel L. Fleishman
    7/25/06       4,782       May 2009  
Marye Anne Fox
    5/11/04       2,000       May 8, 2007  
      5/10/05       2,000       May 8, 2007  
      7/25/06       4,782       May 8, 2007  
Ray J. Groves
    5/10/05       2,000       May 2008  
      7/25/06       4,782       May 2008  
Kristina M. Johnson
    7/25/06       4,782       May 2009  
Ernest Mario
    7/25/06       4,782       May 2009  
N.J. Nicholas, Jr. 
    5/11/04       2,000       May 8, 2007  
      5/10/05       2,000       May 8, 2007  
      7/25/06       4,782       May 8, 2007  
Pete M. Nicholas
    5/10/05       3,000       May 2008  
      7/25/06       7,173       May 2008  
John E. Pepper
    5/11/04       2,000       May 8, 2007  
      5/10/05       2,000       May 8, 2007  
      7/25/06       4,782       May 8, 2007  
Uwe Reinhardt
    7/25/06       4,782       May 2009  
Warren B. Rudman
    5/10/05       2,000       May 2008  
      7/25/06       4,782       May 2008  
 
The following directors deferred receipt of these shares under and in accordance with the terms of our Deferred Compensation Plan:
 
         
Name
  No. of Shares  
Ursula M. Burns
    4,782  
Marye Anne Fox
    4,782  
Ray J. Groves
    4,782  
Kristina M. Johnson
    4,782  
Ernest Mario
    4,782  
N.J. Nicholas, Jr. 
    4,782  
John E. Pepper
    4,782  
Warren B. Rudman
    4,782  
 
(5) No stock options were granted to non-employee directors in 2006. The amounts in this column reflect the expenses related to stock options granted in prior periods and recognized in our 2006 financial statements as described in Statement of Financial Accounting Standards No. 123(R). For a discussion of the valuation assumptions, see Note L to our consolidated financial statements included in our annual report on Form 10-K for the year ended December 31, 2006. Aggregate total numbers of stock option awards outstanding are shown below.
 
                                 
                      Outstanding
 
    Grant
    Expiration
    Exercise
    Stock Options
 
Name
  Date     Date     Price     (Exercisable)  
 
John E. Abele
    5/5/97       5/5/07     $ 12.41       181,000  
      5/10/05       5/10/15     $ 29.75       666  
Ursula M. Burns
    5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
Nancy-Ann DeParle
                       
Joel L. Fleishman
    5/5/97       5/5/07     $ 12.31       8,000  
      5/5/98       5/5/08     $ 18.34       8,000  
      5/4/99       5/4/09     $ 20.63       8,000  
      5/8/01       5/8/11     $ 7.765       4,000  
      5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
Marye Anne Fox
    10/31/01       10/31/11     $ 11.38       4,000  
      5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  


45


Table of Contents

                                 
                      Outstanding
 
    Grant
    Expiration
    Exercise
    Stock Options
 
Name
  Date     Date     Price     (Exercisable)  
 
Ray J. Groves
    5/4/99       5/4/09     $ 20.63       8,000  
      5/8/01       5/8/11     $ 7.765       4,000  
      5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
Kristina M. Johnson
                       
Ernest Mario
    10/31/01       10/31/11     $ 11.38       4,000  
      5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
N.J. Nicholas, Jr. 
    5/5/98       5/5/08     $ 18.34       8,000  
      5/4/99       5/4/09     $ 20.63       8,000  
      5/8/01       5/8/11     $ 7.765       4,000  
      5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
Pete M. Nicholas
    5/5/97       5/5/07     $ 12.31       960,000  
      12/19/97       12/19/07     $ 10.39       56,000  
      12/23/98       12/23/08     $ 12.44       30,000  
      5/9/00       5/9/10     $ 14.16       180,000  
      7/25/00       7/25/10     $ 8.50       180,000  
      12/6/00       12/6/10     $ 6.13       784,500  
      12/17/01       12/17/11     $ 12.5       70,000  
      5/10/05       5/10/15     $ 29.75       1,000  
John E. Pepper
    5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
Uwe Reinhardt
    5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
Warren B. Rudman
    5/9/00       5/9/10     $ 14.16       8,000  
      5/8/01       5/8/11     $ 7.765       4,000  
      5/7/02       5/7/12     $ 12.34       4,000  
      5/6/03       5/6/13     $ 23.255       4,000  
      5/11/04       5/11/14     $ 39.30       1,334  
      5/10/05       5/10/15     $ 29.75       666  
 
(6) The numbers reflected in this column includes all other compensation received by the following directors in 2006:
 
                                                         
    Annual
          Long
          Executive
             
    Founder’s
    Medical
    Term
    Charitable
    Life
    Other
       
Name
  Benefits(a)     Benefits(a)     Care(a)     Donation(a)     Insurance(b)     Perquisites(c)     Total(d)  
 
John E. Abele
  $ 150,000     $ 12,731     $ 8,603     $ 1,000,000     $ 41,394       0     $ 1,214,165  
Pete M. Nicholas
  $ 225,000     $ 11,119     $ 12,744     $ 1,000,000     $ 163,106     $ 23,049     $ 1,436,448  
 
 
  (a)  Amounts included in these columns reflect payments to each of our founders upon their retirement as employees as described below.
 
  (b)  Amounts in this column attributable to Mr. Abele include imputed income and a gross-up amount of $17,282 to cover related tax obligations related to the termination of a previously established split dollar life insurance program. Amounts attributable to Mr. Pete Nicholas include amounts to fund premiums for universal life insurance and imputed income related to the termination of a previously established split dollar life insurance program and a gross up amount of $72,822 to cover related tax obligations.
 
  (c)  This column includes amounts paid for transportation services for Mr. Pete Nicholas.
 
  (d)  This column also includes incidental amounts that fall below the required disclosure thresholds.
 

46


Table of Contents

In May 2005, Pete M. Nicholas, our co-founder and Chairman of the Board, and John E. Abele, our co-founder, retired as employees of Boston Scientific. In connection with their retirement:
 
  •  Mr. Nicholas receives an annual payment of $225,000 for life, and medical coverage under our benefit policies for as long as he remains a director or “director emeritus.” We will continue to fund his existing long-term care insurance and executive life insurance. Mr. Nicholas will continue to have the use of an office at our Natick headquarters or other Boston Scientific facilities and secretarial and administrative support, on an as-needed basis. We will also make a one-time charitable donation of up to $1 million to any qualified charitable organization designated by Mr. Nicholas; and
 
  •  Mr. Abele receives an annual payment of $150,000 for life, and medical coverage under our benefit policies for as long as he remains a director or “director emeritus.” We will continue to fund his existing long-term care insurance and executive life insurance. Mr. Abele will continue to have the use of an office at our Natick headquarters or other Boston Scientific facilities and secretarial and administrative support, on an as-needed basis. We will also make a one-time charitable donation of up to $1 million to any qualified charitable organization designated by Mr. Abele.
 
Mr. Nicholas continues to serve on our Board of Directors and will receive the Chairman of the Board compensation as described above. Mr. Abele continues to serve on our Board of Directors and will receive the non-employee director compensation as described above.


47


Table of Contents

 
EXECUTIVE OFFICERS
 
Our executive officers as of March 31, 2007
 
As of March 31, 2007, our executive officers were:
 
     
Name
 
Title
 
James R. Tobin
  Director, President and Chief Executive Officer
Donald S. Baim
  Senior Vice President and Chief Medical and Scientific Officer
Mark C. Bartell
  Senior Vice President, Global Sales & Marketing, CRM
Lawrence C. Best
  Executive Vice President, Finance and Administration and Chief Financial Officer
Brian R. Burns
  Senior Vice President, Quality
Fredericus A. Colen
  Executive Vice President, Operations and Technology, CRM and Chief Technology Officer
Paul Donovan
  Senior Vice President, Corporate Communications
James Gilbert
  Group President, Cardiovascular
Jeffrey H. Goodman
  Executive Vice President, International
William Kucheman
  Senior Vice President and Group President, Interventional Cardiology
Paul A. LaViolette
  Chief Operating Officer
William F. McConnell, Jr. 
  Senior Vice President, Administration, CRM
Stephen F. Moreci
  Senior Vice President and Group President, Endosurgery
Kenneth J. Pucel
  Executive Vice President, Operations
Lucia L. Quinn
  Executive Vice President, Human Resources
Paul W. Sandman
  Executive Vice President, Secretary and General Counsel
 
Additional information about our executive officers
 
Biographical information concerning our executive officers and their ages can be found under the caption “Directors, Executive Officers and Corporate Governance” in our 2006 Annual Report on Form 10-K for the year ended December 31, 2006, which is incorporated by reference into this Proxy Statement.


48


Table of Contents

 
STOCK OWNERSHIP
 
Stock ownership of our largest stockholders
 
Set forth below are stockholders known by us to beneficially own more than 5% of our common stock. In general, “beneficial ownership” includes those shares a person or entity has the power to vote or transfer, and stock options that are exercisable currently or within 60 days. Unless otherwise indicated, the persons and entities named below have sole voting and investment power over the shares listed. The table below outlines, as of January 31, 2007, the beneficial ownership of these individuals and entities. As of January 31, 2007, there were 1,480,340,219 shares of our common stock outstanding.
 
 
                         
    Number of
             
    Shares
    Percent of
       
    Beneficially
    Shares
       
Name and Address
  Owned     Outstanding        
 
Pete M. Nicholas
    92,686,695(1 )     6.3 %        
c/o Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760
                       
Promerica, L.P
    80,718,018(2 )     5.5 %        
Pete M. Nicholas, General Partner
                       
c/o The Bollard Group
One Joy Street
Boston, MA 02108
                       
 
 
(1) Includes 80,718,018 shares of common stock held by Promerica, L.P., separately presented, a family limited partnership of which Pete M. Nicholas is general partner and as to which he is deemed to have beneficial ownership, 3,350,086 shares held jointly by Pete M. Nicholas and his spouse, with whom he shares voting and investment power, 10,173 shares of restricted stock subject to certain forfeiture provisions granted pursuant to our 2003 Long-Term Incentive Plan, as to which Mr. Nicholas has sole voting but not investment power, and 2,261,500 shares subject to exercisable options granted pursuant to our 1995 and 2000 Long-Term Incentive Plans. Also includes 152,000 shares held by Pete M. Nicholas, Llewellyn Nicholas and Anastasios Parafestas, as trustees of an irrevocable trust for the benefit of Mr. N. J. Nicholas, Jr.’s children as to which Pete M. Nicholas disclaims beneficial ownership. Excludes 1,315,001 shares of stock held by Ruth V. Lilly Nicholas and N. J. Nicholas, Jr., as Trustees of an irrevocable trust for the benefit of Pete M. Nicholas’ children and spouse, as to which Pete M. Nicholas disclaims beneficial ownership. Mr. Nicholas maintains margin securities accounts at brokerage firms, and the positions held in such margin accounts, which may from time to time include shares of our common stock, are pledged as collateral security for the repayment of debit balances, if any, in the accounts. As of December 31, 2006, Mr. Nicholas held 5,867,347 shares of our common stock in such accounts.
 
(2) These shares are also included in the shares held by Pete M. Nicholas, separately presented, because as general partner of Promerica, L.P., Mr. Nicholas is deemed to have beneficial ownership of these shares. Promerica, L.P. maintains a credit line account and a margin securities account at brokerage firms, and the positions held in such accounts, which may from time to time include shares of our common stock, are pledged as collateral security for the repayment of debit balances, if any, in the accounts. As of December 31, 2006, Promerica, L.P. held an aggregate of 80,718,018 shares of our common stock in such accounts.
 


49


Table of Contents

Stock ownership of our directors and executive officers
 
The following table shows, as of January 31, 2007, the amount of our common stock beneficially owned by:
 
(1) our directors and director nominees;
 
(2) our executive officers named in the Summary Compensation Table above; and
 
(3) all of our directors and executive officers as a group.
 
 
                 
    Number of Shares
    Percent of
 
Name
  Beneficially Owned     Shares Outstanding  
 
John E. Abele(1)
    58,753,886       4.0 %
Ursula M. Burns(2)
    36,282       *  
Nancy-Ann DeParle(3)
    54,782          
Joel L. Fleishman(4)
    164,099       *  
Marye Anne Fox(5)
    38,096       *  
Ray J. Groves(6)
    59,949       *  
Kristina M. Johnson(7)
    60,009          
Ernest Mario(8)
    202,282       *  
N.J. Nicholas, Jr.(9)
    1,531,583       *  
Pete M. Nicholas(10)
    92,686,695       6.3 %
John E. Pepper(11)
    58,182       *  
Uwe E. Reinhardt(12)
    51,782       *  
Warren B. Rudman(13)
    49,782       *  
James R. Tobin(14)
    3,422,227       *  
Lawrence C. Best(15)
    2,461,869       *  
Fredericus A. Colen(16)
    343,674       *  
Paul A. LaViolette(17)
    1,330,956       *  
Paul W. Sandman(18)
    796,766       *  
All directors and executive officers as a group (29 persons)(19)
    164,872,047       11.0 %
 
 
Reflects beneficial ownership of less than one percent (1%) of our outstanding common stock.
 
(1) Includes 3,540,500 shares of stock held by a charitable trust of which Mr. Abele shares voting and investment control, 6,782 shares of restricted stock subject to certain forfeiture provisions granted pursuant to our 2003 Long-Term Incentive Plan, as to which Mr. Abele has sole voting but not investment power, 361,438 shares of common stock held by a trust of which Mr. Abele shares voting and investment control and 181,666 shares subject to exercisable options granted pursuant to our 1995 Long-Term Incentive Plan. Also includes 400,000 shares held by Mary S. Abele, Mr. Abele’s spouse, with respect to which Mr. Abele disclaims beneficial ownership. Mr. Abele maintains a credit line account and a margin securities account at brokerage firms, and the positions held in such accounts, which may from time to time include shares of our common stock, are pledged as collateral security for the repayment of debit balances, if any, in the accounts. As of December 31, 2006, Mr. Abele held an aggregate of 45,471,288 shares of our common stock in such accounts.
 
(2) Includes 10,000 shares of common stock subject to exercisable options granted pursuant to our 2000 Long-Term Incentive Plan and 12,782 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plans. Excludes 8,410 common stock equivalents which Ms. Burns has deferred pursuant to our Deferred Compensation Program offered to non-employee directors.
 
(3) Includes 50,000 shares of common stock subject to exercisable options granted pursuant to legacy Guidant stock option plans assumed by Boston Scientific and 4,782 shares of restricted stock subject to certain tax withholding and forfeiture provisions, granted pursuant to our 2003 Long-Term Incentive Plan, as to which Ms. DeParle has sole voting but not investment power.
 
(4) Includes 46,000 shares of common stock subject to exercisable options granted pursuant to our 1992 Non-Employee Directors’ Stock Option and 2000 Long-Term Incentive Plans, and 8,742 shares of restricted stock, subject to certain tax withholding and forfeiture provisions, granted pursuant to our 2000 and 2003 Long-Term Incentive Plans, as to which Mr. Fleishman has sole voting but not investment power and 4,000 shares of restricted stock granted pursuant to our 2000 Long-Term Incentive Plan and deferred pursuant to our Deferred Compensation Program offered to non-employee directors. Excludes 12,750 shares held by a charitable foundation of which Mr. Fleishman is the president and as to which Mr. Fleishman disclaims beneficial ownership. Mr. Fleishman maintains margin securities accounts at brokerage firms, and the positions held in such margin accounts, which may from time to time include shares of our common stock, are pledged as collateral security for the repayment of debit balances, if any, in the accounts. As of December 31, 2006, Mr. Fleishman held 105,317 shares of our common stock in such accounts.
 
(5) Includes 14,000 shares of common stock subject to exercisable options granted pursuant to our 1992 Non-Employee Directors’ Stock Option and 2000 Long-Term Incentive Plans, 704 shares owned by Dr. Fox’s spouse as to which she disclaims beneficial ownership and


50


Table of Contents

16,782 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plans. Excludes 8,581 common stock equivalents which Dr. Fox has deferred under our Deferred Compensation Program offered to non-employee directors.
 
(6) Includes 30,000 shares of common stock subject to exercisable options granted pursuant to our 1992 Non-Employee Directors’ Stock Option and 2000 Long-Term Incentive Plans and 20,782 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plans. Excludes 22,232 common stock equivalents which Mr. Groves has deferred under our Deferred Compensation Program offered to non-employee directors.
 
(7) Includes 55,227 shares of common stock subject to exercisable options granted pursuant to legacy Guidant stock option plans assumed by Boston Scientific and 4,782 shares of restricted stock granted pursuant to our 2003 Long-Term Incentive Plan. Excludes 636 common stock equivalents which Dr. Johnson has deferred under our Deferred Compensation Program offered to non-employee directors.
 
(8) Includes 3,333 shares of common stock subject to exercisable options granted pursuant to our 2000 Long Term Incentive Plan, 20,000 shares held by a self-directed IRA, 50,000 shares held by Mario Family Partners, a family limited partnership of which Dr. Mario is general partner and is deemed to have beneficial ownership, 16,700 shares held by Dr. Mario’s spouse as to which he disclaims beneficial ownership and 20,782 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plans. Excludes 12,528 common stock equivalents which Dr. Mario has deferred under our Deferred Compensation Program offered to non-employee directors.
 
(9) Includes 23,334 shares of common stock subject to exercisable options granted pursuant to our 1992 Non-Employee Directors’ Stock Option and 2000 Long-Term Incentive Plans, 62,466 shares of stock held by N. J. Nicholas, Jr., as sole trustee of a revocable trust and 1,315,001 shares of stock held by Ruth V. Lilly Nicholas and N. J. Nicholas, Jr., as trustees of an irrevocable trust for the benefit of Pete M. Nicholas’ children and spouse as to which N. J. Nicholas, Jr. disclaims beneficial ownership, 75,000 shares held in an IRA, 35,000 shares held in a charitable trust of which Mr. Nicholas is a trustee and to which Mr. Nicholas disclaims beneficial ownership and 20,782 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plans. Excludes 152,000 shares held by Pete M. Nicholas, Llewellyn Nicholas and Anastasios Parafestas, as Trustees of an irrevocable trust for the benefit of N. J. Nicholas, Jr.’s children as to which N. J. Nicholas, Jr. disclaims beneficial ownership and 26,393 common stock equivalents which N. J. Nicholas, Jr. has deferred pursuant to our Deferred Compensation Program offered to non-employee directors.
 
(10) Includes 80,718,018 shares of common stock held by Promerica, L.P., a family limited partnership of which Pete M. Nicholas is general partner and as to which he is deemed to have beneficial ownership, 3,350,086 shares held jointly by Pete M. Nicholas and his spouse, with whom he shares voting and investment power, 10,173 shares of restricted stock subject to certain forfeiture provisions granted pursuant to our 2003 Long-Term Incentive Plan, as to which Pete M. Nicholas has sole voting but not investment power, and 2,261,500 shares subject to exercisable options granted pursuant to our 1995 and 2000 Long-Term Incentive Plans. Also includes 152,000 shares held by Pete M. Nicholas, Llewellyn Nicholas and Anastasios Parafestas, as trustees of an irrevocable trust for the benefit of N.J. Nicholas, Jr.’s children as to which Pete M. Nicholas disclaims beneficial ownership. Excludes 1,315,001 shares of stock held by Ruth V. Lilly Nicholas and N. J. Nicholas, Jr., as Trustees of an irrevocable trust for the benefit of Pete M. Nicholas’ children and spouse, as to which Pete M. Nicholas disclaims beneficial ownership.
 
(11) Includes 6,000 shares of common stock subject to exercisable options granted pursuant to our 2000 Long-Term Incentive Plan, 4,000 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plans subject to certain forfeiture provisions, as to which Mr. Pepper has sole voting but not investment power, 2,400 shares owned by Mr. Pepper’s spouse as to which he disclaims beneficial ownership and 4,782 shares of restricted stock granted pursuant to our 2003 Long-Term Incentive Plan. Excludes 3,143 common stock equivalents which Mr. Pepper has deferred under our Deferred Compensation Program offered to non-employee directors.
 
(12) Includes 10,000 shares of common stock subject to exercisable options granted pursuant to our 2000 Long-Term Incentive Plan and 4,782 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plan subject to certain forfeiture provisions, as to which Dr. Reinhardt has sole voting but not investment power. Also includes 14,000 shares of stock held jointly by Dr. Reinhardt and his spouse, with whom he shares voting and investment control.
 
(13) Includes 22,000 shares of common stock subject to exercisable options granted pursuant to our 1992 Non-Employee Directors’ Stock Option and 2000 Long-Term Incentive Plans, 1,000 shares of stock owned by Senator Rudman’s spouse as to which he disclaims beneficial ownership and 20,782 shares of restricted stock granted pursuant to our 2000 and 2003 Long-Term Incentive Plans. Excludes 21,535 common stock equivalents which Senator Rudman has deferred under our Deferred Compensation Program offered to non-employee directors.
 
(14) Includes 3,312,500 shares of common stock subject to exercisable options granted pursuant to our 1995, 2000 and 2003 Long-Term Incentive Plans. Also includes 9,727 shares held in Mr. Tobin’s 401(k) account.
 
(15) Includes 2,221,000 shares of common stock subject to exercisable options granted pursuant to our 1995, 2000 and 2003 Long-Term Incentive Plans and 8,680 shares held in Mr. Best’s 401(k) account.
 
(16) Includes 258,174 shares of common stock subject to exercisable options granted pursuant to our 1995, 2000 and 2003 Long-Term Incentive Plans.
 
(17) Includes 1,282,250 shares of common stock subject to exercisable options granted pursuant to our 1995, 2000 and 2003 Long-Term Incentive Plans and 12,412 shares held in Mr. LaViolette’s 401(k) account.
 
(18) Includes 760,000 shares of common stock subject to exercisable options granted pursuant to our 1995, 2000 and 2003 Long-Term Incentive Plans and 2,900 shares of stock held by Mr. Sandman as custodian for his child as to which he disclaims beneficial ownership. The balance (except four shares) is held jointly by Mr. Sandman and his spouse, with whom he shares voting and investment control.
 
(19) Please refer to footnotes 1 through 18 above. Includes 13,133,852 shares of common stock subject to exercisable options granted pursuant to our Non-Employee Directors’ Stock Option and 1992, 1995, 2000 and 2003 Long-Term Incentive Plans.


51


Table of Contents

Executive Stock Ownership Guidelines
 
Our executive officers are required to have a significant personal investment in Boston Scientific through their ownership of our shares. In February 2007, the Board adopted stock ownership guidelines for executive officers in the following amounts: